CA2444629A1 - Implantable prosthetic or tissue expanding device - Google Patents

Implantable prosthetic or tissue expanding device Download PDF

Info

Publication number
CA2444629A1
CA2444629A1 CA002444629A CA2444629A CA2444629A1 CA 2444629 A1 CA2444629 A1 CA 2444629A1 CA 002444629 A CA002444629 A CA 002444629A CA 2444629 A CA2444629 A CA 2444629A CA 2444629 A1 CA2444629 A1 CA 2444629A1
Authority
CA
Canada
Prior art keywords
keratin
implant
disc
intervertebral disc
based material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002444629A
Other languages
French (fr)
Inventor
James F. Zucherman
Ken Y. Hsu
Scott Yerby
Robert A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keraplast Technologies Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2444629A1 publication Critical patent/CA2444629A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/12Mammary prostheses and implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/44Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/441Joints for the spine, e.g. vertebrae, spinal discs made of inflatable pockets or chambers filled with fluid, e.g. with hydrogel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/44Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442Intervertebral or spinal discs, e.g. resilient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/30Inorganic materials
    • A61L27/306Other specific inorganic materials not covered by A61L27/303 - A61L27/32
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • A61F2002/2817Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30006Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in density or specific weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30009Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in fibre orientations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30535Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30581Special structural features of bone or joint prostheses not otherwise provided for having a pocket filled with fluid, e.g. liquid
    • A61F2002/30586Special structural features of bone or joint prostheses not otherwise provided for having a pocket filled with fluid, e.g. liquid having two or more inflatable pockets or chambers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30667Features concerning an interaction with the environment or a particular use of the prosthesis
    • A61F2002/30677Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2002/30971Laminates, i.e. layered products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/44Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442Intervertebral or spinal discs, e.g. resilient
    • A61F2002/4435Support means or repair of the natural disc wall, i.e. annulus, e.g. using plates, membranes or meshes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/44Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442Intervertebral or spinal discs, e.g. resilient
    • A61F2002/444Intervertebral or spinal discs, e.g. resilient for replacing the nucleus pulposus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0015Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in density or specific weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0028Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in fibre orientations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00365Proteins; Polypeptides; Degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/04Materials or treatment for tissue regeneration for mammary reconstruction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/38Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs

Abstract

A keratin hydrogel-filled implantable prosthetic device is claimed. The device is an implant for the intervertebral disc space. One source of keratin is human hair. The device (504) can comprise envelopes of a keratin hydrogel (502) that may be used for partial or full disc replacement. The envelopes may be encased in an outer wall (506).

Description

IMPLANTABLE PROSTHETIC OR TISSUE EXPANDING DEVICE
Field of the Invention The present invention is generally related to medical prostheses or implants for augmentation, tissue expansion or replacement of soft tissue, including breast implants and vertebral disc, nucleus and annulus replacements. In particular, the present invention is related to implants ftlled with a keratin hydrogel.
Background of the Invention Breast augmentation and reconstruction through medical procedures have been performed by physicians for decades. Early attempts using filler materials alone, without an enclosing envelope, had less than optimal long-term effects on appearance and health.
The use of silicone gel-filled silicone envelopes gave improved long-term appearance but has created concerns fox manufacturers, surgeons and patients due to possible leakage of the silicone gel from the envelopes into the body. These concerns had the effect of removing silicone gel-filled breast implants from some markets, such as the United States. Saline-filled breast implants have been used in place of the silicone-filled implants. The use of saline has led to fewer concerns, but saline-filled silicone implants have been reported as having a less natural shape and consistency.
Another issue in flee field of breast reconstruction and in the healing of open wounds is the use of tissue expanders. Tissue expanders typically include a bladder or envelope that will hold a liquid such as saline. The expander is placed over a wound, or may be implanted under tissue, such as under the muscles below a surgically removed breast. During use in breast reconstruction, a small amount of saline is added to the envelope periodically until the desired size is reached. By adding liquid slowly over a period of weeks or months, the covering tissue is allowed to expand to accommodate its size. Tissue expanders may also be used to cover an open wound and serve as a platform for the growth of new skin over the wound. Unfortunately, in order to change the volume of the tissue expander a needle must be inserted into the envelope, thus requiring penetration of the tissue and causing pain and an increased possibility of infection.
What would be desirable is a safe, non-toxic, non-antigenic material for use in implants that has a consistency more like that of the original human soft tissue. A further advantage would be an implant that can be implanted using potentially minimally invasive surgical procedures. What would be desirable is a tissue expander that is able to absorb fluid from the patient after implantation so that the expander could reach the desired size without repeated intrusive procedures.
Summary of the Inyention The present disclosure addresses the shortcomings of the prior art by providing a safer, more natural appearing implant for augmenting or reconstructing the human breast or other tissue such as intervertebral disc, nucleus, or annulus tissue, and penile, testicular, gluteal, or facial tissue. Preferred implants include an outer envelope made of silicone or a biocompatible polymer and having an interior containing a keratin hydrogel.
The hydrogel can be made from a keratinous material that is obtained from a biological source, especially keratin obtained from hair, feathers, hooves, feet, beaks, skin or nails of a mammal. The keratin is preferably obtained from hair, and more preferably from human hair. Human hair is especially desirable because of its ready availability as cuttings from barber and beauty shops, because human hair is likely to have less antigenicity in a human subject, and because hair can be harvested from the intended implant recipient. In certain embodiments implants include a hydrogel formed from hydrating a keratin material prepared as described in commonly assigned U.S.
Patent Application Serial No. 09/394,782, incorporated herein by reference. Tn certain embodiments implants include a keratin hydrogel formed using an alternative method as described in U.S. Patent Nos. 5,932,552 and 6,159,496, and in commonly assigned U.S.
Patent Application No. 09/736,957 all incorporated herein by reference.
In more detail, a keratin hydrogel for use in the prosthetic devices described herein may be formed by adding an aqueous solvent such as water to a hydratable keratin material. This hydratable material can be made by a first process beginning with providing a keratinous material including keratin having disulfide bonds and partially oxidizing the keratin disulfide bonds, such that sulfonic acid residues are formed. The sulfonic acid containing keratin material can subsequently be placed in a solvent containing rations, preferably monovalent rations. In certain preferred embodiments, a solution containing the oxidized keratin material is neutralized, or raised to a pH that is less acidic than the oxidation solution. Without limiting the patent to a particular mechanism, in certain embodiments, and depending on the solvent used, the pH
may be raised to a level above the pKa of the sulfonic acid groups to obtain sulfonic acid groups in an anionic state, or having a negative charge. It is contemplated that anionic sulfonic acid groups may more easily form ionic associations or even ionic bonds with the cations. When a substantial part of the liquid is removed from the keratin/cationic solution, a salt or solid salt including the keratin and cations may be isolated. This solid is hydratable, highly absorbent, and forms a hydrogel upon re-hydration. The solid may be used in fibrous or powdered form, and adding water to the solid forms a viscoelastic hydrogel suitable for use as a prosthetic implant filler.
A preferred source of keratinous material is human hair, although the keratin may be obtained from hair or fur of animals including any mammal, from finger or toenail material or from hooves, or from the beaks, feet or feathers of birds. Human hair is a preferred source of keratin because of its ready availability from cuttings of barber and beauty shops, because it is expected to be less prone to cause undesirable immune or allergic reactions in a human should any leakage occur, and because a keratin preparation may be made from the hair of a subject for whom the preparation will be used.
This last advantage can be especially important in embodiments involviug subdermal implantations.
It is well known in the art that keratins are highly sulfated, that is, the amino acid sequence of keratin contains a high proportion of cysteine residues as compared to proteins in general. These cysteines each include a sulfhydryl moiety that is able to bond with another sulfhydril moiety from another cysteine residue to form a disulfide bond known as a cystine residue. The second cysteine may reside within the same keratin molecule, or in another keratin molecule. These disulfide bonds are responsible for much of the tertiary and/or quaternary structure of this class of proteins. A
suitable oxidizing agent is able to break this disulfide bond and to oxidize one or both of the sulfide moieties so that they are no longer able to form a disulfide. Such an oxidation is a part of the process of forming the keratin products of the present disclosure. Preferred oxidizing agents include, but are not limited to peracetic acid, hydrogen peroxide, perborates, percarbonates, benzoyl peroxide, ox ammonium sulfate peroxide.
However, any suitable oxidizing agent known in the art can be used in the practice of the invention.
After oxidation, the liquid oxidizing agent can be filtered from the oxidized keratin solid, and the solid may be washed to remove residual oxidizing agent, for example.
The resulting solid may then be suspended in a non-aqueous solvent and the pH
may be adjusted upward with base - conveniently to at least neutral pH.
Preferred solvents for this second solution do not include significant water as the water may hydrolyze the peptide backbone during processing. Preferred solvents would include alcohols such as methanol, ethanol, or propanol, for example, and would also include non-aqueous solvents such as acetone and tetrahydrofuran, for example. An effective solvent should be able to solvate a base and should also be able to provide a medium able to keep the keratin sufficiently open to allow ionic associations or interactions between the base cations and anionic sulfonic acid groups in the keratin. Preferred bases include, but are not limited to sodium hydroxide, potassium hydroxide and ammonium hydroxide, which, as is known in the art, would yield or produce sodium, potassium and ammonium ions, respectively, upon entering solution.
The keratin suspension may be heated, and is preferably heated to boiling for a time sufficient to swell the keratin. The keratin suspension may be stirred without heat for a longer period of time to allow a more complete association or reaction between the sulfonie acid groups and the base canons. The continued reaction time at or near room temperature, or even below room temperature while stirring is contemplated by the inventors to allow the base canons to approach and bind to the keratin anionic sites with a lower incidence of peptide backbone degradation that could occur with continued boiling. The canons for use in the present invention, therefore, must be able to interact with the anionic cysteic acid groups in the keratin material. The use of the term "canons"
or "monovalent cations" in the present disclosure and claims is an indication of those canons that are able to form such an interaction. After a sufficient xeaction time, the keratin solid may be removed from the suspension by filtration, for example, and dried, leaving a solid salt formed of the keratin sulfonic acid or cysteic acid groups and base canons. This solid may be shredded into a fibrous form and/or ground into a finely divided powder. This solid may be used in certain embodiments, or it may be hydrated by adding water, for example, and the hydrogel, or viscoelasnc hydrogel thus formed may be used in certain embodiments.
The keratin hydrogel so formed is suitable for use as an implant filler, for example, used to fill a breast implant, or to augment soft tissue for cosmetic, reconstrucnve or aesthetic reasons, or it may be used in a tissue expander. In certain embodiments, a dry keratin hydrogel precursox may be placed in a semipermeable silicone shell, for example and implanted in a body cavity, wound, or scar where new tissue growth is needed. This technique is known in the art to be useful in breast reconstruction, in treatment of male pattern baldness, fox treatment of wounds, birth defects, and the like. This technique can also be used to create an intervertebral disc, nucleus and/or annulus.
The present invention may be described, therefore, in certain aspects as a prosthetic device or implant, or even a tissue expander device, wherein the device includes a composition comprising a hydratable keratin solid to be used as a filler for the device, wherein the solid comprises a keratin where at least a portion of the cysteic groups of the keratin are sonically associated with, or may be sonically bound to cations.
As used herein, sonically bound or sonically associated would have their ordinary meaning as is known in the art, and would include the electrostatic attraction between an anion and a canon, and would include such interactions directly, such as through formation of ionic bonds, and interactions through intermediary bipolar moieties, for example. A cysteic group would include cysteine and derivatives of cysteine including cystine and cysteic acid. As used herein, cysteic acid and sulfonic acid denote a cysteine side chain in which the terminal sulfur is bonded to three oxygen atoms to produce the sulfonic acid ion, S03-, or the acidic form, S03H. In certain embodiments, a portion of the cysteic groups are oxidized to cysteic acid groups. Cysteic acid groups may comprise a significant portion of the total cysteic groups. The extent of the oxidation may be adjusted by adjusting certain parameters of the oxidation reactions, such as temperature, concentration of oxidizing agent, and time of reaction, for example, to achieve a product with certain desired properties, such as absorbency or resiliency, for example.
In certain embodiments, therefore, the hydratable keratin solid is made by a process comprising oxidizing a portion of the disulfide groups of a keratin to obtain a keratin having oxidized cysteic groups, and contacting the keratin having oxidized cysteic groups with monovalent cations under conditions effective to form ionic associations or ionic bonds between at least a portion of the oxidized cysteic groups and the cations.
In some embodiments, the hydratable keratin solid is made by a process comprising oxidizing at least a portion of the disulfide groups of a keratin to obtain a keratin having oxidized cysteic groups, and contacting said keratin having oxidized cysteic groups with monovalent cations under conditions effective to form ionic associations or ionic bonds between a substantial portion of said oxidized cysteic groups and said cations. The oxidization may comprise placing the keratin in a solution containing a concentration of an oxidizing agent effective to oxidize a portion of the disulfide groups. The portion of oxidized disulfide groups may be a major portion of the total cysteic acid groups.
In certain embodiments of the present invention, the oxidation comprises placing the keratin in a solution containing a concentration of hydrogen peroxide, peracetic acid, perborates, percarbonates, benzoyl peroxide, or ammonium sulfate peroxide effective to oxidize a portion of the disulfide groups.
The process of the present invention may further comprise heating the keratin solid containing oxidized cysteic groups in a solvent solution containing a dissolved base. The solvent solution may comprise a solvent selected from methanol, ethanol, propanol, ether, tetrahydrofuran (THF), and acetone. In certain embodiments the process further comprises removing the solution from the heat and stirring for a tinne effective to form ionic bonds between the cysteic acid groups and canons produced by the base. The process may also further comprise drying the keratin solid, such as by drying a solid or solution under vacuum.
Another aspect of the present invention includes prosthetic implants that comprise a keratin hydrogel wherein the hydrogel is produced by adding water to a composition comprising a hydratable keratin solid, wherein the solid comprises a keratin where at least a portion of the cysteic acid groups of the keratin are ionically bound to cations. Tn some embodiments, the hydrogel is a keratin viscoelastic hydrogel produced by adding water to a composition comprising a hydratable keratin solid, wherein the solid comprises a keratin where a portion of the cysteic acid groups of the keratin are ionically bound to or associated with cations.
Another aspect of the present invention is the use in a prosthetic implant of a hydratable keratin solid made by (1) oxidizing keratin in a first solution comprising a soluble oxidizing agent, such that a portion of the disulfide bonds of the keratin are oxidized to form cysteic acid residues, to obtain an oxidized solid fraction;
(2) separating the oxidized solid fraction from the first solution; (3) contacting the oxidized solid fraction with a second, basic solution comprising a monovalent canon dissolved in a solvent; (4) maintaining the second solution containing the oxidized solid fraction and the monovalent cations for a time and at a temperature effective to cause an interaction between the cysteic acid residues and the monovalent cations to obtain a salt solution of the keratin and the monovalent cation; and (5) substantially removing the solvent from the salt solution to obtain a hydratable keratin solid.
The process may also further comprise adjusting the pH of the second solution, to obtain a substantially neutral solution. In some embodiments, the keratin is obtained from hair or fur, and is preferably obtained from human hair.
In some embodiments, the keratin is oxidized by suspending the keratin in a solution of a suitable oxidizing agent, such as one selected from the group consisting of hydrogen peroxide, peracetic acid, perborates, percarbonates, benzoyl peroxide, and ammonium sulfate peroxide, in a concentration of between about 1 and about 35 IO weight/volume percent. In various embodiments, the keratin is oxidized by suspending the keratin in a solution of an oxidizing agent selected from the group consisting of hydrogen peroxide, peracetic acid, perborates, percarbonates, benzoyl peroxide, and ammonium sulfate peroxide, in a concentration of about 1, or about 2, or about 3, or about 4, or about 10, or about 15, or about 20, or about 30, or about 32, or about 35 weightlvolume percent. As used herein the term weight/volume percent refers to a solution in which the concentration is determined in weight percent, that is then diluted into a particular volume, arriving at a weight/volume percent. For example, in order to arrive at the oxidant solutions described herein a "stock solution" at fairly high concentration is diluted in water. As an example, hydrogen peroxide may be purchased as a 30 weight % solution (30 grams of peroxide per I00 grams of solution). To make 1 liter of a 2% solution of this, one would dilute 66.7 mL of the 30 weight %
stock solution in 933.7 mL of water. The net effect is to cut the stock solution 15-fold (from 30 down to 2 %). This ratio is a weight to volume ratio, so the resulting solution is described as 2 weight/volume %.
In. some embodiments, the keratin is oxidized by suspending the keratin in a solution of a suitable oxidizing agent, such as one selected from the group consisting of hydrogen peroxide, peracetic acid, perborates, percarbonates, benzoyl peroxide, and ammonium sulfate peroxide, in a concentration of between about 1 and about 35 weight/volume percent, at a temperature between about 0°C and about 100°C. In other embodiments the temperature is between about 4°C and about 90°C, or between about 20°C and about 100°C, or between about 80°C and about I00°C. In other embodiments, the temperature is about 4°C, or about 90°C, or about 100°C.
The present invention may also include the process wherein the keratin is oxidized by suspending said keratin in a solution of an oxidizing agent selected from the group consisting of hydrogen peroxide, peracetic acid, perborates, percarbonates, benzoyl peroxide, and ammonium sulfate peroxide, in a concentration of between about 1 and about 35 weight/volume percent, at a temperature between about 0°C
and about 100°C for a period of between 0.5 and about 24 hours, or in a concentration of oxidizing agent of between about 1 and about 35 weightJvolume percent, at a tempexature between about 0°C and about 100°C for a period of between 1 and about 2 hours, or for between about 2 and about 4 hours, or for between about 1 and about 4 hours, or for a period of about 10 hours.
More specifically, the process of making the keratin solid may include oxidizing the keratin by suspending the keratin in a solution of between about 1 percent to about 32 percent peracetic acid at a temperature between about 0°C and about 100°C for between about 0.5 and about 24 hours, or by suspending the keratin in a solution of about 1 percent peracetic acid at a temperature between about 0°C and about 100°C for between about 0.5 and about 24 hours, or by suspending the keratin in a solution of between about 4 percent peracetic acid at a temperature of about 4°C for 24 hours, or by suspending the keratin in a solution of about 4 percent peracetic acid at room temperature for about 24 hours, or by suspending the keratin in a solution of about 4 percent peracetic acid at about 90°C for about 10 hours, or by suspending the keratin in a solution of about 4 percent peracetic acid at a temperature between about 20°C and about 100°C for between about 1 and about 4 hours, or by suspending the keratin in a solution of about 4 percent peracetic acid at a temperature between about 80°C and about 100°C for between about 1 and about 2 hours, or even by suspending the keratin in a solution of about 2 percent peracetic acid at a temperature between about 0°C and about 100°C for about 2 hours.
A second solution in the process of making the disclosed keratin compositions, wherein the second solution contains the oxidized solid fraction and monovalent cations may be heated, and may also be boiled for between about 0.5 hours and about 12 hours, fox between about 0.5 hours and about 3 hours, or for about 1 hour. When said solution is boiled, the solution may be allowed to continue xeacting while being stirred after removal of the heat. Alternatively, the solution may be stirred and allowed to react without the application of heat, or of boiling temperatures. In certain.
embodiments, the solution is allowed to react at a temperature of between about 15°C and about 30°C for a period of between about 1 and about 24 hours, or at a temperature of between about 20°C
and about 25°C for a period of between about 1 and about 5 hours, or at room temperature for a period of about 5 hours.
Implants made with a hydratable keratin solid offer particular advantages over other implants, especially in implants that involve a Iarge amount of material, such as breast or gluteal pad implants. In a preferred method of use, the hydratable keratin solid in powder or fiber form may be added to an envelope interior prior to insertion, and water may then be injected into the envelope after implantation, thus forming the hydrogel in situ. In the practice of this embodiment, the implant envelope containing a dry solid will have a small volume relative to the size of the final implant, thereby allowing a relatively small incision for insertion of the implant. In certain applications, it may be more advantageous to implant an empty envelope, again allowing for a relatively small incision, to form a hydrogel outside the body and then injecting the hydrogel into the envelope through a large bore needle, for example. It is also understood that implants may be formed with the hydrogel in. place in the envelope prior to implantation. Such implants are advantageous as intervertebral disc, nucleus and annulus replacements or repairs.
Tissue expanders made with a hydratable keratin solid offer particular advantages over other tissue expanders, especially tissue expanders which require volume adjustments which are made through an externally filled tube. The use of an external filling is often uncomfortable and inconvenient for the patient, and can lead to an increased incidence of infection. In a preferred method of use, the hydratable keratin solid in powder or fiber form may be added to a tissue expander envelope interior. The permeation of body fluids through the envelope can be controlled through the use of certain materials and engineering principle well known to those skilled in the art. The control of the diffusion rate has the effect of controlling the hydration rate of the keratin solid and thus, the expansion rate of the hydrogel thus formed. The expansion rate can thus be controlled in-situ, without the use of an external fill tube. This method of use would lead to a more comfortable and convenient tissue expander with lower incidence of infection. Alternatively, the hydration rate of the keratin solid can be controlled by controlling the absorbency of the keratin solid during manufacture as described herein.
A solid tissue expander formed from an absorbent keratin solid with a controlled absorption rate would have the advantage of expanding its volume at a controlled rate in-situ, and thus providing the same advantages as noted previously.
In certain embodiments implants can be made using a keratin hydrogel formed using a method that does not include a hydratable keratin solid stage. An implantable keratin hydrogel can be made by a process beginning with providing a keratinous material from a biological source, such as hair, fur, feathers, hooves or nails, most preferably human hair, and oxidizing the hair or other keratin material. The oxidized hair can be suspended in a base solution, such as an ammonium hydroxide solution, for example, wherein the solution contains thioglycolate. The solution may then be heated, and stirred under an inert environment such as an N2 environment, for example.
Although the use of a nitrogen environment may be preferred for certain embodiments, any oxidatively inert gas such as argon or helium, for example, may also be used. A
swelled fraction of keratin gel can be separated from the suspension and added to an oxidizing agent such as hydrogen peroxide or peracetic acid, for example.
Alternately, the swelled fraction can be exposed to ambient air. The gel can be allowed to stand in the oxidizing environment, thereby forming a crosslinked hydrogel. This method of forming a crosslinked gel is described more completely in U.S. Patent No.
5,932,552 incorporated herein by reference.
The implant can be made by filling the envelope interior either before or after implantation. In implants filled after implantation, the implant can be rolled into a small profile shape and inserted through a small incision into the interior of a breast or other organ or area to receive an implant. As is well known in the art, an incision for breast replacement may be made in the navel, or near the edge of a mastectomy scar, for example, and incisions for augmentation may also be made in the crease at the bottom of the breast or around the axeolar area of the breast. The envelope can then be unrolled and the hydrogel injected through a large bore needle, using the same incision used to insert the envelope. The injection can be made into a ,self sealing port provided in the envelope. Such embodiments are also suitable for intervertebral disc, nucleus and annulus replacement and repair.
Hair is a preferred source of keratin for the present invention. In particular, human hair is a preferred source. In one method, hair is harvested from the intended implant recipient. While any human hair is believed suitable as a source, the use of hair from the intended recipient may provide a psychological and allergenic advantage relative to hair from other sources.
An object of the present invention is to provide for implants which accomplish intervertebral disc replacement and repair. Such replacement and repair can be to the entire disc or to the nucleus or the annulus associated with the disc.
Replacement and repair can be accomplished through the use of keratin based products of the invention by themselves and in combination with single or multiple envelope arrangements.
Initially repair and/or replacement can also be accomplished with single or multiple layers of the keratin based product of the invention with and without nonwoven felts comprised of a synthetic polymer and/or a keratin based product of the invention. An example of non-woven materials that may be used are described in U.S. Patent Application Serial No.
09/587,157 incorporated herein by reference.
The replacement and repair implants can be shaped to match the portion of the annulus that is being replaced. Further these implants can also transport drugs, living cells, co-factors and/or other materials that can stimulate healing of damaged structures.
Other features and advantages of the invention are presented in the specification and in the claims.
Brief Description of the Figures Fig, la - 1e depict embodiments of the invention including one or more layers which can be used for intervertebral disc replacement ox repair.
Figs. 2a - 2d depict embodiments of the invention wherein nonwoven keratin material is designed to support a load, such as the load exerted on the spinal column.
Fig. 3 depicts an embodiment of the invention using a keratin hydrogel which can be positioned in an intervertebral space.
Fig. 4 depicts an embodiment of the invention wherein keratin hydrogel is encapsulated for positioning within an intervertebral space.
Figs. 5a - Sc depict embodiments of the invention including groups of capsules or envelopes for positioning within an intervertebral space.
Figs. 6a - 6e depict embodiments of the invention relating to annulus and replacement.

Detailed Description of the Invention The present invention arises from the discovery by the present inventors that prosthetic implants, or implants to replace ox augment soft tissues in the body, especially in the human body can be made from a keratin material, and in a most preferred embodiment, from human hair. The implants described herein offer numerous advantages over other implants, especially silicone, saline, or even autogenous fat cells.
These advantages include that the keratin gel implants are less toxic than silicone implants should a leakage occur, keratin gel implants have a more natural look and feel than saline implants, and keratin implants require an incision ox injection only at the site of implant, and do not require a second invasive procedure for harvesting tissue such as fat cells, fox example.
Example 1 Implants Utilizing Keratin Hydro~el from Solid Precursor The present example describes implants having a keratin hydrogel contained within an envelope, where the keratin hydrogel is formed from a solid, keratin hydrogel precursor which forms a keratin hydrogel upon the addition of water. The solid precursor form of kexatin derived implant material may be used in several ways, depending on the need of the practitioner. For example, the solid may be hydrated prior to placing the keratin filler into an implant envelope. In the practice of this method, one would be able to determine precisely the volume of the implant filler prior to placing the filler in the envelope of the implant. The hydrated gel could then be injected into the envelope either before or after the envelope is implanted. It is understood that the invention would include prepackaged, sterile, prefilled, sealed implants as well as a package that includes various sized envelopes and a separately packaged hydrogel, or hydrogel precursor.
In certain embodiments, a solid precursox may be added directly to an implant envelope and subsequently hydrated in the envelope either before or after the envelope is implanted. Again, hydrating the keratin after implantation, ox injecting the hydrated gel into the envelope after implantation both allow a much smaller incision to be made, and allow the injection through the same incision of either water or hydrogel.
This embodiment of the invention would include a packaged implant with a premeasured amount of solid hydrogel precursor, or would include the separate packaging of envelopes and solid precursor.
In the present example, a solid hydrogel precursor can include protein having an ionizable pendant gioup, such as sulfonic acid, or cysteic acid, which can be derived S from an oxidized protein disulfide linkage. A preferred source of protein is keratin, preferably keratin obtained from hair, and most preferably keratin obtained from human hair. While hair is a preferred source of keratinous material, other keratinous materials are also believed suitable for use in the present invention. Examples of other sources include animal hair or fur, skin, hooves, feathers, beaks, feet and horns. The patient or a human donor are some preferred sources of hair, as hair from these sources is most likely to result in a non-antigenic product, although animal hair may be acceptable for many individuals. In one method according to the present invention, hair is provided, preferably clean and unbleached. In another method, the hair is washed with Versa-Clean TM (Fisher Scientific, Pittsburgh, PA), or other cleaners, rinsed with deionized 1 S water, and allowed to dry.
In a preferred method of preparing a solid hydrogel precursor, cleaned hair can be oxidized in peracetic acid or another suitable reagent such as H202. One method utilizes between about 1% to 32% peracetic acid, at a temperature between about 0 degrees C
and 100 degrees C for between O.S and 24 hours. In one method, about I
weightlvolume percent peracetic acid is used. One method treats 30 grams of hair with S00 mL
of 4%
peracetic acid at 4 degrees C for 21 hours. Another method treats the hair at room temperature for 24 hours. Yet another method treats the hair at about 90 degrees C for about 10 hours. In a preferred method, the hair is treated by heating the hair in the oxidizing agent for between about 1 and 4 hours at a temperature between about 20 and 2S 100 degrees C. In a more preferred method, the haix is treated by heating the hair in the oxidizing agent for between about 1 and 2 hours at a temperature between about 80 and 100 degrees C. In a most preferred method, the hair is treated by heating the hair in about 2 weight/volume percent oxidizing agent for about 2 hours at a temperature of about 100 degrees C. The oxidation is believed to cleave a significant portion of keratin disulfide bonds forming cysteic acid residues. The sulfonic acid groups are believed to be hydrophilic in nature and will ionically bond to canons later in the process, forming a salt of the keratin and cation.

After oxidation, the keratin solid can be recovered from the oxidizing liquid using filtration or other suitable methods such as centrifugation or decantation.
The recovered, oxidized solid may be washed with water or any other suitable liquid such as an alcohol, including methanol or ethanol, for example, to remove the excess oxidizing agent.
The solid fraction can be suspended in a suitable solvent. The solvent should be capable of at least suspending the hair or keratin solid and keeping the solid sufficiently swelled for subsequent reaction. The solvent is preferably a non-aqueous solvent, as the presence of water can contribute to hydrolysis of peptide backbone bonds of the protein product, which can result in an inferior product. The solvent should also be able to solubilize the later added cation. One group of suitable solvents includes alcohols such as methanol and ethanol. Other solvents such as ether, tetrahydrofuran (THF), and acetone may also be suitable as solvents. The solvent used is preferably volatile to promote evaporation from the final solid product.
The hair or keratin solvent suspension may then have the pH titrated upward to at least about pH 7, or preferably to a pH at or above the pKa of the sulfonic acid groups of the protein. This increased pH acts to ionize or deprotonate the sulfonic acid groups and allows ionic interactions with cations. The cations are preferably produced by including a base in the solution, preferably a monovalent base, or a base that provides a monovalent cation in solution. Preferred bases include, but are not limited to ammonium hydroxide, sodium hydroxide and potassium hydroxide.
The keratin suspension can be heated for a time and temperature sufficient to swell the keratin structure and promote neutzalizing of the sulfonic acid sites with the provided canon. In a preferred method, the keratin is suspended in ethanol and boiled between about 0.5 hours and 12 hours in the presence of the canon. More preferably, the keratin is suspended in ethanol and boiled between about 0.5 hours and 3 hours in the presence of the cation. In one method, the keratin is suspended in ethanol and boiled for about I hour in the presence of the cation. Boiling for too long a time period is believed to lead to a final, partially solubilized or mushy keratin which may result from degradation of the peptide backbone. A partially solubilized keratin product is less preferred due to the greater difficulty of grinding the keratin.
After boiling, the keratin is preferably allowed to continue to react with the provided base cations at lower temperature and with stirring. The lower temperature reaction preferably takes place at a temperature of between about I S and 30 degrees C

for between about 1 and 24 hours. More preferably, the lower temperature reaction takes place at a temperature of between about 20 and 25 degrees C for between about 1 and 5 hours. In one method, the keratin suspension is allowed to react with stirring at room temperature for about 5 hours.
After ion exchange at lower temperature, the solid salt can be separated from the solvent using any suitable method such as filtration. The solid is preferably washed with a solvent that may be the same solvent as that used in the reaction. Washing the keratin removes excess base, which is preferably removed to make the keratin solid neutral.
After filtration and washing, the keratin can be dried by a method such as evaporation under vacuum. In one method, the keratin is dried at room temperature under about 5 mm Hg vacuum for about 2 hours. The dried keratin is preferably somewhat brittle, which can result in a better product after grinding. The dried keratin can be shredded into fibers or can further be ground into a powder. The dried keratin can be directly ground into a powder using a mortar and pestle, a ball mill, or other means of breaking down or comminuting the dried keratin into particles. Solid keratin hydrogel precursor can be provided in either fibrous or powder form for use in the implant.
The solid keratin hydrogel precursor is capable of absorbing many times its own weight in water. In one test, fibers were shown to absorb an average of 13 times their weight in water at 21.5°C, and may absorb up to 20 times. The absorbed water is chemically bound to the keratin through acid-base interactions such as hydrogen bonding. This results in a stable, viscoelastic hydrogel from which the water cannot be separated by normal mechanical means such as centrifugation or compression.
A patient, the intended recipient, can be prepared for the operation and a small incision made at the breast or other area such as by way of example only, the intervertebral disc area, to receive an implant. The envelope can be rolled into a cylinder or other small shape to decrease the profile and the compacted envelope inserted through the incision. The envelope can be allowed to attain a less constrained shape well known to those skilled in the art, such as a meniscus or soft disc shape. Leaving the envelope empty or containing only a solid hydrogel precursor can greatly decrease the volume of the envelope during insertion. Decreasing the volume can greatly decrease the implant profile and the required incision size. By waiting to inject any fluid into the implant until after implantation, a more minimally invasive procedure can be performed. Tn one method, the envelope includes a self sealing injection port in the envelope wall. A large IS

hypodermic syringe can be used to inject the fluid into the self sealing port.
The large hypodermic is preferably inserted through the already formed incision in the breast or other tissue, to avoid the need for an additional puncture. In embodiments having a keratin hydrogel precursor in the envelope, the injected fluid can be water, thus forming the hydrogel in situ. In embodiments using a preformed hydrogel, the hydrogel can be injected through a preferably large bore needle and into the envelope interior. While the hydrogel can be quite viscous, the needle bore can approach the size of the incision in some embodiments. After implantation, the incision can be closed and allowed to heal.
Such implants can be impermeable, semipermeable and permeable to bodily fluids. Thus for semipermeable and permeable implants, the implant can come to a desired shape and size over time.
Example 2 Tissue Expanders Utilizing Keratin Hydr~el from Solid Precursor The present example describes tissue expanders having a keratin hydrogel contained within an envelope, where the keratin hydrogel is formed from a solid, keratin hydrogel precursor which forms a keratin hydrogel upon absorption of body fluids. A
variety of different sized tissue expanders can be provided by varying the size of the envelope and the amount of keratin hydrogel precursor. In addition, the rate at which the tissue expanders reached their final volume can be varied by controlling the diffusion rate of body fluids into the tissue expander, or by varying the absorbency of the dry keratin solid, as described herein.
A patient, the intended recipient, can be prepared for the operation and a small incision made in or near the breast or other area to receive a tissue expander. Placing the tissue expander in its dehydrated form allows for the implant to absorb body fluids through the envelope at a controlled rate, thus increasing in volume at a controlled rate.
The volume expansion occurs in-situ, after the incision has been closed, and provides a more comfortable and convenient implant when compared to conventional treatments. A
lower incidence of infection would result from having a closed incision without the need for an external fill tube as in conventional tissue expander products.

Example 3 Implants Using Keratin Hydrogel Formed From Keratin With Added Hydrophilic Groups and With Reformed Crosslinks In the present example, an alternate embodiment is described, a keratin hydrogel that is provided using a method that does not involve adding water to a solid keratin hydrogel precursor. The keratin material may be obtained from the same sources as described in Example l, and preferred source of keratin is human hair. In one method, hair is provided, preferably washed and unbleached. The hair is harvested from a human or animal source. The patient or another human donor is a preferred source of hair, as hair from these sources is most likely to result in a non-antigenic product, although animal hair may be acceptable for certain individuals that do not have animal product allergy problems. In one method, the hair is washed with Versa-Clean TM
(Fisher Scientific, Pittsburgh, PA) or other suitable cleansing agent, rinsed with deionized water, and allowed to air dry.
The hair can be oxidized in peracetic acid or another suitable reagent such as H202. A preferable treatment utilizes from 1 % to 32% peracetic acid, at a temperature between about 0 degrees C and 100 degrees C for between 0.5 and 24 hours. One method treats 30 grams of hair with 500 mL of 32% peracetic acid at 4 degrees C for 24 hours. This treatment with peracetac acid is believed to partially oxidize the naturally occurring disulfide linkages to produce a protein with cysteic acid (-CH2S03IT) residues.
The hair is recovered, preferably with filtration through a coarse fritted glass filter, and rinsed numerous times with deionized water until the rinse solution has a pH
of 6.0 or higher. The hair can then be dried in a vacuum oven at between 20 degrees C
and 50 degrees C for between 0.5 and 5 days. One method dries the hair in a vacuum oven at 40 degrees C for several days. The dried hair can then be pulverized and ground into a fme powder. One method of grinding the hair uses a ceramic mortar and pestle.
The keratin powder can be suspended in a sulfhydryl solution such as an ammonium thioglycolate solution, for example. In one method, pulverized keratin powder, derived from hair as described above, is suspended in about 3N
ammonium hydroxide containing thioglycolate. About six grams of keratin powder can be added per 75 mL of 3N ammonium hydroxide solution. The strength of ammonium hydroxide is preferably about 3N and the preferred concentration of ammonium thioglycolate is from about 2 to about 20 ml (as thioglycollic acid) per 75 ml of ammonium hydroxide, or about 11 ml thioglycolate per 75 ml ammonium hydroxide in certain embodiments.
The suspension can then be heated for a time sufficient to solubilize the soluble fraction of the hair. The suspension in one method is heated to between 50 degrees C and degrees C for between 1 and 24 hours, followed by cooling. In a preferred method, the suspension is heated to about 60 degrees C for about 4 hours and cooled to room temperature.
Applicants believe this treatment cleaves the remaining disulfide linkages to produce cysteine residues in the protein structure. At his point, the keratin protein is believed to contain sulfonic acid, sulfhydril and cystine-thioglycolate containing residues. The ratio of sulfonic acid residues and sulfliydril residues can be controlled by varying the time, temperature, and concentration of oxidant in the peracetic acid treatment step previously described. The presence of sulfonic acid residues imparts a hydrophilic property to the hair as well as to the final hydrogel product.
After the treatment described above, a keratin fraction resistant to the treatment remains, consisting primarily of beta keratin. This fraction is insoluble in the suspension and is removed in one method by centrifugation at about 10,000 g for about 10 minutes.
The insoluble fraction is set aside anal is available for other uses. A thick, j elly-like supernatant remains which includes a soluble keratin fraction. The supernatant is collected and used to make the implant material described herein.
The supernatant is preferably purified, using a method such as dialysis. A
preferred method uses dialysis against running water using a dialysis membrane (Spectra/Por T1V1) having a cutoff of about 8000 MW. The resulting solution is preferably concentrated to a concentration of about 0. 1 grams per mL.
The keratin in solution is now ready for crosslinking to form a hydrogel. In a preferred method, an oxidizing agent is added to the keratin to crosslink the keratin proteins. Preferred oxidizing agents include oxygen, hydrogen peroxide, organic peracids, peroxy carbonates, ammonium sulfate peroxide, benzoyl peroxide, and perborates. Hydrogen peroxide is preferably added to the keratin solution at about 0.5%
to about 1.0% w/v, mixed well, and allowed to stand at room temperature for several days. A preferred standing time is about 3 days. The freely flowing solution slowly thickens and converts to a crosslinked hydrogel after about 72 hours.
The insoluble keratin fraction from hair is thus partially oxidized so as to have the protein backbones interconnected with disulfide linkages and having sulfonic acid residues. The partially oxidized keratin is treated with a reducing agent to cleave some or all of the remaining disulfide bonds, forming thiol groups and cystine-thioglycolate groups and to solubilize more of the keratin proteins. After removing the insoluble fraction, the keratin is oxidized to allow the formation of disulfide crosslinks. Disulfide crosslinks are thus reformed. As used herein, the term "reformed" refers to crosslinks broken and formed Iater in time, where individual linkages Iater formed could be, but are not necessarily, between the same amino acid cysteine pairs.
A crosslinked, pure keratin hydrogel results. The hydrogel has sulfonic acid groups which are hydrophilic and bind water within the hydrogel. The number of sulfonic acid groups corresponds to the degree of keratin oxidation in the partial oxidation step.
In one method for implanting the envelope, the hydrogel is formed by adding the oxidizing agent to the keratin supernatant outside of the envelope followed by mixing.
After a time period, the mixed hydrogel and oxidizing agent or other crosslinking agent can be injected into the implant envelope. In some procedures, the envelopes are prefilled with keratin hydrogel prior to packaging the implant. In some procedures, the envelopes are filled with keratin hydrogel by injection only after implantation of the envelopes. Tn some procedures, the oxidizing agent and keratin supernatant are mixed close to the time of the surgical procedure, and the mixture injected soon after mixing, before the mixture becomes very viscous. In these procedures, the mixture can be allowed to thicken in situ.
The present invention includes hollow implants which can have a thicker envelope wall than those commonly used in breast implants. A keratin hydrogel can be used to fill any hollow implant envelopes known in the art, including penile implants, testicular implants, chin implants, intervertebral implant including but not limited to intervertebral disc, nucleus and annulus implants, and gluteal pad implants.
Numerous advantages of the invention covered by this disclosure have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of substitutions of chemically or biologically equivalent substances, or in the order of steps in certain methods without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.

Example 4 Intervertebral Disc Space Repair and Replacement Implants The present embodiments relate to intervertebral disc space repair and replacement implants. More particularly, by way of example only, disc, nucleus and annulus replacement implants and repair implants are discussed. It is to be understood that the teachings of the rest of the specification apply equally well to the embodiments presented in this Example 4.
In many patients suffering from back pain, disc extrusion or nerve impingement, it may be desirable to provide support for the annulus, if present. The annulus, in general, contains t he nucleus, which provides vertical support against compressive loads and maintains the disc height. When a disc nucleus degenerates, it loses water, becomes weakened, and thereby does not provide sufficient vertical support for the body weight.
The annulus can provide some lateral support for a normal and also for a weakened disc nucleus. However, it does not support vertical loads very well. If Othe nucleus becomes too weak, or if the annulus is damaged through injury or disease, the annulus may not provide sufficient structural support for the body weight, and a portion of a disc nucleus can be extruded from within the intervertebral space, forming a Aherniated disc.@
Thus, surgical repair, reconstruction or replacements of herniated discs, eroded discs, and missing discs is often a challenging problem. Annulus repair is also a solution which has been given little or no attention. However, using keratin-based materials, and encapsulations of these materials, as described throughout this specification, significant improvement in the function of the disc, nucleus, andlor annulus can be provided. Thus, this invention includes implantable disc replacements and repairs having keratin based materials therein. Disc replacement can comprise a nucleus replacement, an annulus replacement, or both. Depending on the subject=s need, the entire annulus, the nucleus or a portion thereof can be replaced or repaired.
Nucleus Replacements or Repair - Generally Nucleus replacements can include gels and/or gels in flexible containers. In certain embodiments in which a portion of the natural disc is functional, only a damaged or ineffective, part of the original nucleus need be replaced. In other embodiments of this invention, when a substantial portion of the nucleus is ineffective, it can be desirable to replace more of the nucleus. In further embodiments, it may be necessary to replace the entire original nucleus with an artificial disc replacement. Nucleus replacements of this invention can include keratin products. Keratin products include non-woven keratin, keratin gels, and keratin products which contain keratin peptides. Examples of keratin peptides that may be included are described in U.S. Patent Application Serial No.
09/330,550, incorporated herein by reference.
Depending on the site of nucleus replacement, the material can desirably be selected to resist the pressures to be encountered at that site. For example, the lower lumbar spine typically is exposed to greater vertical stresses than the cervical spine. This is, in general, because the body weight and muscle forces are greater at the lumbar spine than at the cervical spine, which typically needs only to support the weight of the head.
Additionally, during flexion, the loads on the posterior annulus are greater than on the anterior annulus.
Therefore, in certain embodiments, it can be desirable to provide nucleus replacement materials having stress-strain relationships that can minimize the likelihood of the portion of the nucleus from becoming completely compressed. In certain embodiments, a material having a stress-strain relationship wherein there is relatively little compression with increased compressive stress can be made by providing a denser material or by providing an incompressible material such as a hydrogel in a relatively rigid containment device, or capsule. Alternatively, in situations in which relatively less stress needs to be supported, a less dense non-woven material or a gel in a relatively more flexible containment device can be used.
A. Nucleus Replacements or Repairs of Non-Woven Keratin Non-woven keratin nucleus replacements of embodiments of this invention can be in the form of a fibrous network or felt. The non-woven product can be formed either as single layer material or as multiple layered sheets. In some embodiments, different layers of keratin material can be used. For example, one sheet of keratin can be formed having a selected fiber size, density and/or degree of sulfonation or other charge bearing moieties. A second sheet can be formed having a different fiber size, density, degree of sulfonation and/or other characteristic. Such laminates can thus have certain selected properties on one face and other properties on the other face. In other embodiments, multiple layers of keratin material can be used, in which different layers can have different selected charge, charge density, density, fiber length or other properties.

In. alternative embodiments, the keratin non-woven nucleus repair or replacement can also have natural or synthetic polymer materials as laminates and/or as non-woven co-precipitates. Laminates can be made by preparing separate layers of polymer materials and then adhering them together. Laminates can also be made by forming a subsequent layer on top of an akeady formed layer. In certain embodiments, laminates can be made having three or more layers of polymer material. For example, a laminate can be prepared having a top layer of keratin, a middle layer of a synthetic polymer, and a bottom layer of keratin. Such three-layered laminates can provide the advantages of keratin on the surface of the repair or replacement, while providing desirable properties such as mechanical strength and flexibility to the disc replacement. In similar fashions, multiple layered laminates can be manufactured to have a variety of properties in each lamina. Additionally, with multiple layers of a synthetic polymer, each layer can have a different orientation in order to achieve certain mechanical functionality such as enhanced strength and other properties.
Figures 1 a - 1 a depict embodiments of this invention. Figure 1 a depicts a non-woven keratin sheet 100 having a uniform thickness. Figure 1b depicts a bilayered nucleus replacement having a layer of keratin 102 and a layer of another polymer 104.
Figure lc depicts a multilayered nucleus replacement comprising a keratin layer 106 and polymer layer 108. Figure 1d depicts a co-precipitated nucleus replacement 110. Figure 1 a depicts a multilayered nucleus replacement having multiple layers 112, 114, 116 of keratin material having different properties.
Co-precipitates can be made by preparing solutions of the keratin material and other polymer materials) separately, mixing the solutions together, and then drying the resulting mixture to form a felt that contains both keratin and the other polymer(s). The resulting non-woven product therefore contains desirable features of keratin, including being relatively inert, as well as desirable features of the non-keratin polymer(s). Such non-keratin polymers referred to in this specification can include by way of example only polyester, polyethylene, poly(tetrafluoro)ethylene, polypropylene, silicones and other polymers known in the art.
Uses of Non-Woven Keratin Nucleus Replacements or Repair In certain embodiments, felts comprising keratin can be provided having a shape that can be either pre-formed or can be prepared at the site of surgery to conform to the desired intravertebral space. The disc replacement can be provided as a sheet of uniform thickness, with top and bottom faces being substantially parallel, and can advantageously be used in situations in which the faces of adjacent vertebral bodies are substantially parallel. In alternative embodiments, non-woven material can be provided that has unequal thickness to accommodate non-parallel surfaces of adjacent vertebral bodies.
For example, in the lumbar and sacral spine, the dorsal aspects of the vertebral bodies are generally closer together than the ventral aspects. Thus, a wedge-shaped nucleus replacement can be used with a thinner aspect of the disc replacement positioned near the dorsal aspect of the vertebral bodies, and a thicker aspect can be positioned near the ventral aspect. Thus, when in use, the normal curvature of the lower lumbar spine can be well supported by the disc replacement.
In other locations, for example in the thoracic spine, the ventral aspects can be closer together than the dorsal aspects. In these situations, it can be desirable to position a wedge shaped nucleus replacement wherein the thinner portion of the disc replacement is near the ventral aspect and the thicker portion is positioned near the dorsal aspect.
In yet other embodiments, in which the intervertebral space is more uniform in thickness, it can be desirable to provide nucleus replacments having more uniform thickness.
In certain situations in which the intervertebral space is irregularly shaped, a surgeon can adapt a pre-formed nucleus replacement to suit the patient=s particular needs. Thus, if a vertebral body defect results in an abnormally large depression in one region of a vertebral body, the surgeon can select a relatively thick replacement and remove portions of the replacement so that the inserted replacement can fit more beneficially within the patient=s intervertebral space.
Example Embodiment of Intervertebral Disc Replacement B Layered Sheet Material Figures 2a - 2d depict embodiments of this invention wherein non-woven keratin material is designed to support the load.
Figure 2a depicts a uniform non-woven nucleus replacement 200 of this invention. The nucleus material has an approximately circular area and a thickness designed to provide cushioning support between two adjacent vertebral bodies.
Figure 2b depicts an alternative embodiment in which the non-woven nucleus replacement 202 has non-uniform thickness.

Figure 2c depicts another embodiment of this invention in which the non-woven nucleus replacement 204 has an irregular thickness to accommodate an uneven intervertebral space.
Individual sheets of a keratin-based material will be layered and molded into the shape of an annulus fibrosis 206. Concentric layers of a keratin-based sheet material will be applied to one another about a central, vertical axis until a thickness of approximately 1 to 2 cm is achieved. The layers will be formed such that there is an outer Layer and an inner layer. Approximately 10 to 20 individual layers will be used. Thus each of the inner layer and the outer layer can be formed of one or multiple individual layers or sheets of keratin-based material. Each sheet or layer can be comprised of the non-woven or the woven type with keratin-based material deposited thereon as described herein. For strength the alternating sheets can have directionally different structural strengths depending on the orientation of the non-woven or woven material and how it is formed.
Thus if the elements or fibers of the material have directionality, the sheets can be combined so that the directionality of each sheet is different from the next.
The sheets can be formed one and then the next on top of the first in order to make the layers or the sheets can be glued together with glues that are known in the art.
It is to be understood that if an inner layer and an outer layer structure is formed, that the inner layer would be more favorably compatible with the below described keratin-based hydrogel 208, while the outer layer could for example be more structurally capable of carrying the load due to the strength and number of the sheets that comprise the outer layer. Also for such an embodiment which is meant to be a full or partial disc replacement implant, the disc implant can have an upper and a lower portion.
In figure 2c the lower portion is shown. The upper portion would be similar. In figure 2c, the lower portion includes sheets of non-woven or woven material or both, some or all of which have deposited thereon keratin-based materials. In addition, as with the annulus, the individual sheets can have directionally different structural properties.
As indicated below, either or both of the sheets and the hydrogel can include one or both of cells and/or growth factors. The inner volume of the layered material will be filled with a keratin-based hydrogel 208. The prosthetic intervertebral disc will be positioned in the place of an excised, degenerated intervertebral disc and bonded to the endplates via fibrous ingrowth. The layered keratin-based material and keratin-based hydrogel may or may not contain cells and/or growth factors. The growth factors may or may not induce host cells to migrate or differentiate and produce a fibrous ingrowth between the layered keratin and endplate, and produce hydrophilic proteoglycans. In addition, the impregnated cells or host cells may produce connective proteins to secure the the keratin-based layers to the endplate. Also, the impregnated cells or host cells may produce hydrophilic proteoglycans.
The resulting intervertebral disc prosthesis should be meet the following kinematic requirements: +/- 3 deg flexion, +/- 5 deg flexion/extension, +/- 3 deg lateral bending. In addition, the disc must be able to withstand 1200 N of compression and 2.5 MPa of internal pressure. The approximate dimension of the prosthesis should be 6 to 20 mm in height, 30 to 70 mm in width, and 30 to 50 mm in depth.
Adjuncts to Keratin Materials In certain embodiments, it can be desirable to include other, non-polymer materials with keratin materials. For example, it can be desirable to include drugs, cells, co-factors, and/or other materials that can stimulate healing of damaged structures. In certain embodiments, it can be desirable to include antiinflammatory agents, such as non-steroidal antiinflammatory drugs (NSAIDs) to decrease infiltration of undesirable inflammatory cells into the intervertebral space. In other embodiments, it can be desirable to include certain cytokines, such as interleukins, bone growth promoting peptides, keratin peptides, vitamins, enzyme inhibitors and/or other materials known in the art.
Keratin Nucleus Replacements and Repair Containing Living Cells In yet other embodiments, it can be desirable to include living cells in the nucleus replacement or repair. In situations in which the disc collagen has been damaged, chondrocytes can be provided within the nucleus replacement material to provide a source of new chondrocytes. When chondrocytes are stimulated to grow and produce new collagen the intervertebral space can become augmented with naturally occurring collagen.
In other embodiments, wherein bony portions of the vertebral bodies are damaged due to injury or disease, it can be desirable to provide a keratin nucleus replacement containing osteoblasts or osteocytes, either alone or along with osteogenic materials such as bone morphogenetic proteins (BMPs) which can promote cell growth and division or differentiation and secretion of extracellular materials needed for regrowth of the missing tissue.
In these embodiments, after implantation, the keratin materials can provide growth scaffolds for the proper growth of chondrocytes, fibrochondrocytes, fibroblasts, osteoblasts and/or osteocytes. Once the intervertebral space has been repopulated with proper cells, those cells can be made to differentiate and produce cartilage, bone or other structural tissues.
In certain embodiments, the use of fibroblasts, fibrochondrocytes, chondrocytes, osteoblasts and osteocytes can be desirable to promote the healing and regrowth of damaged or injured vertebral bodies and nuclei .
In these situations, it can be desirable for the keratin material to have a biological lifetime that is compatible with the replacement of cartilage. Thus, as new cartilage grows, the keratin can be biodegraded and removed, making more room in the intervertebral space for newly formed cartilage.
E. Keratin Gel Nucleus Replacements and Repairs Keratin gels can be desirable in situations in which a relatively rigid nucleus replacement is not desired. Such situations include those portions of the spine where flexibility is desired, such as the cervical spine, or in areas in which vertical stresses change widely during, for example, postural changes.
Keratin gel-based nucleus replacements can have different forms. For example, in certain embodiments, a gel by itself can be used. Being a protein, keratin has some intrinsic strength and therfore resistance to compression. Using a keratin gel along with non-woven keratin material can provide a degree of flexibility as well as flexibility to the disc replacement. In certain embodiments, keratin gels can be used without additional non-woven keratin material. In other embodiments, a keratin gel can be placed within a capsule or envelope.
The load bearing capacity of a keratin gal-containing capsule is related to intrinsic resistance by the gel of a compressive load and the ability of a capsule or envelope to contain the pressure within the capsule or envelope generated by the load. By varying the composition of the gel and the size and configuration of the capsule, different load and flexibilities can be provided for a disc replacement. For example, a stiff keratin hydrogel can be used with a relatively weak capsule to provide an equivalent load bearing capacity as a weaker keratin hydrogel and a relatively stronger capsule.

1. Gels Without Capsules - Generally Certain embodiments of this invention include keratin hydrogels as nucleus replacements or repairs having no containment device. For these embodiments, it can be desirable for the gel to have sufficiently low bioresorbability and sufficient stability so that after placement, the gel remains within the interveterbral space without any additional structural support. Keratin gels used in this way desirably have sufficient physical and chemical characteristics so that when hydrated to their proper volume in situ, the gel tends to resist water expression and compression of the gel, thereby decreasing the thickness of the disc replacement or repair and resulting in a close approximation of the vertebral body surfaces.
To resist such water expression and gel compression, in certain embodiments, gels of this invention can have sufficiently large numbers of electrical charges to retain water through Van der Wahls forces, ionic interaction or dipole-dipole interactions.
1S Because keratin gels comprise proteins made of amino acids, polar and/or charged amino acids can take part in forming hydrated gels. Additionally, because keratin has numerous cysteic acid residues that can be oxidized to form sulfonic acid residues, the degree of sulfonation can affect the ability of a hydrogel to retain water. By increasing the number of sulfonic acid residues in a strand of keratin, more negatively charged moieties can be present. Sulfonic acid groups, being charged, can bind water molecules, dissolved inorganic ions such as Na+ (sodium), K+ (potassium) and other cations.
In solutions of water and ions, such as physiological media including the extracellular milieu, cations are typically hydrated through Van der Wahls forces, ionic interactions and/or dipole interactions. A water molecule is made of one oxygen atom and two hydrogen atoms. The two hydrogen atoms are covalently bonded to the oxygen atom with bond angles relative to each other of about 1090. Oxygen is more electronegative than hydrogen, so the hydrogen oxygen atoms do not equally Ashare@
the electrons that make up the oxygen hydrogen covalent bond. Rather, the oxygen tends to attract the electrons more closely to its nucleus, and results in a molecule having a net dipole, with the oxygen atom having a net partial negative charge and the two hydrogen atoms each having a net partial positive charge. Thus, in liquid media having cations, water molecules tend to arrange themselves with the electronegative oxygen atoms being closer to the positive charges of the cations, thus tending to neutralize the charge separation between the ion and the water molecule. A single ion is like a Ahub@ and the water molecules are like Aspokes@ of a wheel. This results in a Ashell@ of water molecules surrounding the Asolvated@ ration. As a result, the hydrogen atoms, with their relative electropositivity, tend to be oriented centrifugally, or away from the S solvated ration. Thus, a first shell of water tends to have a net partial positive charge.
A second shell of water molecules can be arranged around the first shell. In the second shell, as described above, the oxygen atom is relatively electronegative and tends to remain close to the hydrogen atoms of the first shell. Thus, the second shell has water molecules arranged as spokes with the oxygen atoms nearer the solvated ion and the hydrogen atoms more distant. Subsequent shells of water can be formed, but as more shells are present, the orientation of the water molecules becomes less ordered, so that at some distance from the solvated ration, the water molecules are attracted together as they are in free solution, with no ration being present.
Each solvated ion has different net charge and size. Thus, a sodium atom, being I S smaller than potassium can attract water molecules and bind them more closely to its nucleus than a potassium ion, which is larger. Thus, the size of a solvated ion/water complex (Ahydrated radius@) is larger for sodium than for potassium.
In a similar fashion, anions (negatively charged ions) have hydrated radii that can depend on the charge of the ion. Thus, a sulfonic acid residue which has three oxygen atoms bound to a sulfur atom, there are three locations where a partial negative charge can reside. Therefore, hydration shells can be formed around each of the oxygen atoms.
In addition to ionic and other charge-related effects, colloid osmotic effects can contribute to hydration of gels. Large molecular weight materials, such as proteins can foam colloids in solution, and by vitrue of being solvated, contribute to colloid osmotic 2S pressure, which can resist a tendency for the material to be compressed.
Thus, if water is bound tightly to the keratin, it is less likely to be forced away by hydrostatic pressure resulting from compression of the disc replacement by body weight.
Conversely, if water is less tightly bound to the keratin or other material, water can be more easily expressed from the disc replacement and the disc material can become thinner.
In addition to charge/hydration effects, the total number of charges and the number of keratin molecules can affect the ability of a disc replacement to withstand compressive stress. Thus, increasing the amount of keratin, andlor increasing the sulfonation of the cysteic acid residues on the keratin can incxease the ability of the keratin to retain a desirable shape within the intervertebral space.
In practice, one can measure the colloid osmotic pressure of keratin-based gels of this invention using standard methods known in the art. In general, it can be desirable for a keratin based gel to be able to remain hydrated at pxessures corresponding to the Ioad on the disc replacement while in use.
Figure 3 depicts an embodiment of this invention in which a non-encapsulated keratin hydrogel, which can be positioned within intervertebral spaces is deposited.
Figure 3 depicts a keratin hydrogel 300 having relatively high polymer content IO and binds a relatively large amount of water. In this embodiment, the gel layer has a thickness that provides satisfactory separation of two adjacent vertebral bodies. Under load the gel becomes compressed by the extrusion of some water. However, sufficient water has been retained so that adjacent vertebral bodies do not impinge on one another.
After the Load is decreased, the gel can re-hydrate to maintain satisfactory separation of the adjacent vertebral bodies. Extrusion and re-hydration provide nutrients to cells and remove waste.
Example Embodiment of a Nucleus Pulposis Implant With no Envelope:
The implant is comprised of a keratin-based hydrogel 302 placed in the space previously occupied by the degenerated nucleus pulposis. After the degenerated nucleus pulposis is removed, the hydrogel material may be delivered to the space via a syringe and needle, or a trephine and tamp or other methods used by those skilled in the art.
Typically 0.5 to 6 cc of material will be needed to fill the evacuated space.
The hydrogel material may be placed in the dehydrated, partially hydrated, or fully hydrated state. The hydrogel may be used as a carrier for growth factors 304 and/or cells 306. The compressive strength should be approximately 1 Ml'a, but preferably closer to 4 MPa.
The hydxogel material should have equilibrium water content of between 75% to 90% by weight and a fixed charge density of approximately 0.28 meq/ml B both of which can be altered by the oxidation process. The oxidation and grinding process alters fixed charge density and surface area of the hydrogel material respectively. As the oxidation level is increased, the fixed charge density of the material increases. However, there is a threshold to the process, afterwhich, fixed charge density decreases. Also, as the material is ground to a finer powder, the surface area increases and more water can be bound. Again, there is a minimum threshold to particle size after which the material will no longer strongly bond to water.
The hydrogel is intended to restore the intervertebral disc height, place the annulus fibrosis in tension, and restore the diffusion/pumping mechanism used to supply nutrients to the intervertebral disc cells and remove waste products from the disc. If the hydrogel is seeded With cells, the restored pumping mechanism will provide nutrients to these cells and remove their waste products. If seeded with growth factors, the existing cells will proliferate and the nutrient supply will be maintained by the restored pumping mechanism. Likewise the waste products will be removed through the newly restored pumping mechanism.
Cells that may be added to the hydrogel may include fibrochondrocytes cultured from the annulus fibrosis or nucleus pulposis, chondrocytes, or fibroblasts.
In addition, precursor mesenchymal stem cells may be added to the hydrogel. All cells are added to the hydrogel with the intent to promote matrix generation within the nucleus pulposis.
Growth factors that may be added to the hydrogel include any factor from the TGF-beta family, VEGF, FGF, any keratin-based growth factor or any other factor that may induce cell differentiation, migration, andlor glycosaminoglycan production in the nuclear space.
The growth factors will be added to the hydrogel with the intent of promoting nuclear matrix generation through induction, migration, and/or cellular production of matrix proteins.
2. Encapsulated Gels In other embodiments of this invention, gels can be encapsulated to maintain their integrity under load-bearing conditions. Such encapsulation can be effected using polymer based materials, such as silicones, or can be keratin based, for example, using non-woven keratin material.
Suitable encapsulating polymers can include, by way of example only, polyethylene, poly(tetrafluoro)ethylene, polystyrene, polyester, silicone, and other synthetic polymers known in the art. Additionally, in some embodiments, it can be desirable to encapsulate a leeratin hydrogel within a keratin capsule, such as a non-woven capsule. In certain embodiments, it can be desirable for the capsule to be non-porous, that is, to keep keratin, ions and water within the capsule. Alternatively, it can be desirable to provide a capsule having pores to permit the movement of water and/or small ions (e.g, sodium, chloride and the Like) into and out of the capsule.
Synthetic and non-synthetic polymers with pores of various sizes are known in the art. Pores can be made of a desired size sufficient to (1) keep water, ions and keratin within the capsule; (2) keep ions and keratin within the capsule; or (3) keep only keratin and/or other high molecular weight materials within the capsule.
1. Non-Porous Capsules and Envelope - Generally In certain embodiments of this invention, it can be desirable to keep the water and ions within the capsule. For such embodiments, capsules having pores sufficiently small so that water molecules do not pass through. With these embodiments, the nucleus replacement may be able to withstand higher loads without substantial loss of thickness.
When a hydratable keratin is placed within such a capsule, water and ions can make contact with the keratin material. Upon hydration, the keratin material can swell to form a hydrogel. Thus, one role of the porous capsule is to keep the keratin materials positioned within the intravertebral space to provide support to the spine. As pressure on a nucleus replacement increases with increasing load, some of the water and/or ions might be extruded from the hydrogel, leave the capsule, and possibly leave the intravertebral space, thus, permitting a degree of compression of the capsule.
2. Water-Permeable Ion-Impermeable Capsules and Envelope - Generally In other embodiments, it can be desirable for the sizes of the pores to be sufficiently small so that solvated ions are retained within the capsule, and for water to be able to leave. For these embodiments, the degree of compression of the nucleus replacement can be less than for embodiments in which ions can be extruded as well as water. By retaining ions within the capsule, more osmotically active particles can be retained within the capsule than in embodiments in which ions are extruded from the capsule.
Figure 4 depicts an embodiment of this invention in which keratin hydrogel 402 is encapsulated for positioning within an intervertebral space.
Figure 4 depicts an embodiment in which the precursor or hydrogel encapsulating material 400 is non-porous. Under load, the disc replacement is not compressed.
Alternatively, the precursor or hydrogel encapsulating material 400 can be porous, and can have pores sized to permit the passage of water, but not ions or keratin polymers therethrough. In this embodiment, the load on the capsule is sufficient to extrude a small portion of the water, but the keratin material within the capsule retains sufficient water to keep the thickness of the nucleus replacement sufficient to maintain a desired separation of adjacent vertebral bodies.
3. Capsules Permeable to Water and Ions - Generally Figure 4 depicts an embodiment in which the precursor or hydrogel encapsulating material 400 is porous and has pores sized to permit the passage of water and solvated ions, but not large enough to permit passage of keratin materials. In this embodiment, the load on the capsule is sufficient to extrude some water and solvated ions, but the keratin material within the capsule retains sufficient water to keep the thickness of the disc sufficient to maintain a desired separation between adjacent vertebral bodies of a portion of the spine under flexion.
Such disc replacements can be useful in situations in which it is desirable for the dimensions of the nucleus replacement to be varied with the load. One example is in situations in which a degree of flexion is desired.
In yet other embodiments, the capsule can be made more or less flexible. By providing a relatively flexible capsule, the hydrogel within can move about in response to the subject's movements, without the capsule being damaged. In subjects having relatively mild damage, such flexible encapsulated keratin disc replacements can be especially useful to maximize spinal mobility.
Encapsulated keratin hydrogels can be made of differing sizes. In one series of embodiments, a capsule can be made sufficiently large to occupy substantially the entire area between vertebral bodies. Such Aunitary@ encapsulated gels can be especially useful for subjects in which the entire original disc must be replaced. It can be desirable for such unitary gels to have encapsulating material of sufficient strength to withstand the wall tension tending to pull the capsule material apart. It is known that for a cylinder, there is a relationship between the hydrostatic pressure, the radius of the cylinder and the wall tension necessary to keep the pressure within the cylinder contained. The relationship is known as LaPlace=s law for a cylinder, and can be expressed by the following relationship:
delta P = T, r where delta P is the pressure across the wall of a capsule (Atransmural pressure@
= pressure inside - pressure outside) of the cylinder, r is the radius and T
is the wall tension. It can be appreciated that the ability of a material to withstand wall tension depends on the intrinsic strength of the material and the wall thickness.
Thus, for materials having large intrinsic strength, the thickness of the wall can be less than for weaker materials.
Example Embodiment for a Nucleus Pulposis Implant B Single envelope The keratin-based hydrogel 402 described herein may be placed in an envelope 400 comprised of a keratin-based material or alternatively a suitably non-keratin based material. The envelope material may be in the form of a sheet material that may or may not include two external polyester layers and an inner keratin-based material.
The sheet material may be processed in the form of a closed, continuous capsule. The envelope may be permeable or impermeable to cells, growth factors, andlor fluids.
Permeability is based on the ability of the above mentioned items to freely pass through the envelope barner. The hydrogel may be placed in the envelope prior to implantation in the nucleus cavity or after implantation. The hydrogel may be injected, poured, or tamped into the envelope. The hydrogel may be dehydrated, partially hydrated, or fully hydrated. The envelope may be sealed before or after the keratin hydrogel is placed.
The envelope may be impregnated with cells and/or growth factors and may be designed to bond to the vertebral endplates andlor annulus fibrosis. Cells that may be added to the hydrogel may include fibrochondrocytes cultured from the annulus fibrosis or nucleus pulposis, chondrocytes, or fibroblasts. In addition, precursor mesenchymal stem cells may be added to the hydrogel. All cells are added to the hydrogel with the intent to promote matrix generation within the nucleus pulposis. Growth factors that may be added to the hydrogel include any factor from the TGF-beta family, VEGF, FGF, any keratin-based growth factor or any other factor that may induce cell differentiation, migration, and/or glycosaminoglycan production in the nuclear space. Bonding between the envelope and host tissue may be in form of fibrous ingrowth. This fibrous ingrowth may involve ftbrocartilage formation between the annulus fibrosis and/or cartilaginous endplates and the envelope. The newly generated fibrous tissue may form within the pores andlor on the surface of the envelope and span to the endplates and/or annulus tissue. Bonding may also be facilitated by using an adhesive. Such adhesives are known in the art.

The envelope may or may not be flexible or expandable and may or may not allow for changes in volume. Flexibility is defined as the ability of the material to change shape upon application of load, but not necessarily volume.
Expandability and compressibility are defined as the ability of the material to change volume upon load application. The changes in volume would be a direct result of the addition or subtraction of water from the hydrogel within the envelope. If the hydrogel imbibes fluid the volume will increase, and if fluid is released, the volume will decrease.
The volume and dimensions of the envelope will be equal to or less than the volume of the evacuated nucleus pulposis space.
4. Multi Chamber Embodiments In other embodiments, it can be desirable to provide smaller encapsulated gels.
For example, a group of relatively small gel capsules can be positioned within an intervertebral space. Each of such a group can provide some of the load-bearing functions. It can be readily appreciated that cylinders having the same wall tension and smaller radii can withstand greater transmural pressures than cylinders having larger radii. Thus, according to LaPlace=s relationship, small capsules can withstand greater transmural pressures and loads than larger capsules. It can also be readily appreciated that even with relatively large capsules, one can provide greater load bearing capability by increasing the amounts of keratin, ions, and/or water within the capsule.
If a portion of the load is borne by the keratin material within the capsule, less load need be borne by the capsule material.
Figure Sa - Sc depict embodiments of this invention in which groups of capsules are positioned within an intervertebral space.
Figure Sa depicts an embodiment 500 in which 4 capsules 502 are provided for positioning within an intervertebral space of a subject having all the original disc replaced.
Nucleus Pulposis Implant B individual Envelopes The hydrogel described above will be placed in individual envelopes 504 and multiple envelopes will be placed in the evacuated nuclear space. The envelopes are similar those described earlier; they may be permeable or impermeable, they may be impregnated with growth factor and/or cells, and they may or may not conserve volume during deformation. Multiple individual envelopes may be placed in the intervertebral disc and may or may not be placed in one or more larger envelopes that contains) all of the smaller envelopes.
Figure Sb depicts an embodiment 504 in which 7 capsules 506 are provided for positioning within an intervertebral space of a subject having a complete disc replacement. An outer wall 506 can be used as desired to encase the inner capsules.
Nucleus Pulposis Implant B continuous, mufti-chambered envelope:
The envelope described above may be mufti-chambered 508. The pathways connecting the multiple chambers may be designed to restrict the flow rate of the hydrogel from one chamber to another. In addition, the individual chambers may be positioned to direct the hydrogel from one anatomic area to another during motion.
In certain other embodiments, it can be desirable to provide a network of small capsules, connected together using tubes through which keratin hydrogel can move.
Figure Sc depicts an embodiment 508 of this invention in which several small capsules are in fluid communication with the other capsules in the group by way of connecting tubules. In such embodiments, increased load on one capsule can cause the hydrogel to flow throught the tubules to other capsules. Such a situation can occur during spinal flexion. For example, if a subject with such an embodiment bends forward, the load placed on ventral portions of adjacent vertebral processes increases. This then increases the load placed on those capsules near the ventral side of the vertebrae. The increased load causes hydrogel to be extruded into more dorsal capsules. It is to be understood that the embodiments of Figure Sa-Sc can also be used on partial replacements of the disc.
Annulus Replacements -Generally In certain subjects, the nucleus may be intact and relatively healthy, but the annulus may have suffered injury or disease, weakening the annulus to a point at which it 2S may not support the nucleus sufficiently to prevent herniation, extrusion or destruction.
In these subjects, it can be desirable to replace a portion of the annulus with an exogenous material. Non-woven keratin materials can be provided that have sufficient strength to resist stretching and thereby can be used to augment or replace damaged annular materials. The strength necessary to prevent stretching can be approximated by LaPlace=s law for cylinders, described herein above. Because the lateral load withstood by the annulus can be affected by the radius, the thickness of the material and the intrinsic strength of the nnulus replacement can be selected so that the total wall tension during use does not exceed the strength of the annulus replacement.
In one series of embodiments, non-woven keratin material can be used as a single Layer sheet. In other embodiments, multiple layers of keratin material can be used. In S other embodiments, annular replacements can comprise multilayered structures having layers of keratin and other polymers, such as polyester, polypropylene, silicone, and others known in the art as described above for nucleus replacements. Moreover, in yet other embodiments, an annulus replacement can comprise co-precipitated polymers, wherein keratin and another type of polymer is formed in fashions as described above.
As with nucleus replacements, in certain embodiments, it can be desirable to include adjuncts in an annulus replacement. Such adjuncts include NSAIDS, cytokines, growth factors, or other molecules described herein or as known in the art.
Also, as with nucleus replacements, it may be desirable to include cells in an annulus replacement.
Such cells can include osteoblasts, chondrocytes, fibroblasts or other cells whose 1S presence can improve the healing or the post-surgical function of the annulus. In particular, fibroblasts can synthesize collagen, an extracellular fibrous protein that can strengthen the tissue. Osteoblasts can synthesize hydroxyapatite, a bone matrix material, and thereby strengthen the portion of an annulus replacement near bony tissues.
Chondrocytes can synthesize chondroitin sulfate and other extracellular components of cartilage, and thereby provide in situ replacement of nucleus material and connective tissues.
In situations in which a partial annulus replacement or support is to be provided, it can be desirable to attach the annulus replacement to the remaining annulus, the vertebral bodies or to other tissues near the affected intervertebral space with. sutures, 2S adhesives, and other methods known to one of ordinary skill in the art.
Such tissues include the bone, periosteum, ligaments, endplates and the remaining annulus.
Such attachments can help localize the annulus replacement to those sites where it can have beneficial function. Also, such attachment can provide load bearing capability, if desired. For example, due to the wall tension applied on the annulus due to the LaPlace relationship previously described, attaching the annulus to the upper and lower vertebral bodies can help reduce the load between the existing, damaged annulus and the annulus replacement.

Example Embodiment for Annulus Fibrosis Repair B sheet material:
Penetrations, defects, or damage to the annulus fibrosis may be repaired using a keratin-based material. The material may be placed at the damaged area to induce a repair response from the surrounding tissues arid provide a scaffold for the repair response to take place. The material may be in the form of a sheet 600 that is placed on the inner and/or outer wall of the damaged annulus 602. The material 606 may be in the form of a plug 604 that is placed in the defect. The material 606 may also be securely anchored and tethered to the opposite inner annular wall 608. The purpose of each embodiment is to maintain its initial placement postion during the repair process, repair the damaged annulus fibrosis and restore the pressure-vessel characteristics of the annulus. After the repair process takes place, the annulus should be able to provide restraint to the hydrostatic compression produced in the nucleus pulposis during loading, i.e. the annulus should act as a pressure vessel.
One aspect of the present invention is a nonwoven film composition comprising a synthetic polymer and a keratin material for use in annulus repair. The synthetic polymer may be, but is not limited to, a-olefins, acrylates, urethanes, acetates, nylon, esters, and copolymers thereof. An a-olefin is considered to be any monomer containing an a-double bond. The nonwoven composition may also further comprise a natural material which may be, but is not limited to, cotton. In some embodiments of the invention, the nonwoven composition is a laminate, which may be, but is not limited to, a tri-laminate comprising two outer layers of synthetic polymer and a middle layer of keratin material.
The keratin material in the middle layer may be partially exposed by openings in the two outer nonwoven synfihetic polymer layers. In some embodiments of the invention the synthetic polymer layers are nonwoven webs of polymer fibers. In other embodiments of the invention the synthetic polymer layers are nonwoven webs of polymer fibers.
Figures 6d - 6e also depict annulus replacements of this invention. Figure 6d depicts a partial annulus replacement, wherein a portion of damaged original annulus is removed and replaced with a keratin based non-woven or woven sheet 600. Figure 6e depicts a complete annulus replacement 600, wherein a sheet of keratin material is adhered to the upper and lower vertebral bodies using adhesive.

Annulus replacements can be premade having a variety of different sizes, thicknesses, compositions and physical properties. The surgeon can evaluate the needs of a particular patient and provide a properly sized annulus replacement during surgery.

Claims (65)

What is claimed is:
1. An intervertebral disc implant comprising:
a layer of keratin material which is adapted to be inserted between adjacent vertebral bodies.
2. The intervertebral disc implant of claim 1 including:
another layer of a polymer.
3. The intervertebral disc implant of claim 1 including:
another layer of a synthetic polymer.
4. The intervertebral disc implant of claim 1 including:
said layer be capsulated in one of the polyethylene, poly(tetrafluoro)ethylene, polystyrene, polyester, silicone, and other synthetic polymers.
5. The intervertebral disc implant of claim 1 including:
said layer of keratin material comprising a keratin hydrogel.
6. The intervertebral disc implant of claim 1 including the layer including keratin material deposited on a non-woven material.
7. The intervertebral disc implant of claim 1 including:
the layer including keratin material deposited on a woven material.
8. The intervertebral disc implant of claim 1 including:
the non-woven material being a polymer.
9. The intervertebral disc implant of claim 1 including:
the woven material being a polymer.
10. The intervertebral disc implant of claim 1 including:
another layer of a keratin material.
11. The intervertebral disc implant of claim 1 including:
a plurality of layers at least one of which is another layer of a keratin material and at least one is a layer of a polymer.
12. The intervertebral disc implant of claim 1 including:
said layer of a keratin material sandwiched between layers of a polymer material.
13. The intervertebral disc implant of claim 1 including:
said layer of keratin material shaped in a wedge shape in order to be adapted to fit between adjacent vertebral bodies.
14. The intervertebral disc implant of claim 1 including:
said layer of keratin material being irregularly shaped in order to be adapted to fit between adjacent vertebral bodies.
15. The intervertebral disc implant of claim 1 including:
said layer for partially replacing a nucleus of a vertebral disc.
16. The intervertebral disc implant of claim 1 including:
said layer for replacing the entire nucleus of a vertebral disc.
17. The intervertebral disc implant of claim 1 including:
said layer for at least partially replacing a nucleus and an annulus of a vertebral disc.
18. The intervertebral disc implant of claim 1 including:
said layer including at least one of growth factors, and living cells.
19. An intervertebral disc implant comprising:
one or more layers of a keratin-based material formed in the shape of a disc annulus; and a keratin-based hydrogel filling the shape of the disc annulus.
20. The intervertebral disc implant of claim 19 wherein said layers are concentric layers of a keratin-based material.
21. The intervertebral disc implant of claim 19 wherein:
at least one of the layers include keratin-based material deposited on non-woven material.
22. The intervertebral disc implant of claim 19 wherein:
at least one of the layers including keratin-based material deposited on a woven material.
23. The intervertebral disc implant of claim 21 wherein said non-woven material is a polymer.
24. The intervertebral disc implant of claim 22 wherein said woven material is a polymer.
25. The intervertebral disc implant of claim 19 wherein said layers are porous.
26. The intervertebral disc implant of claim 19 wherein said layers are non-porous.
27. An intervertebral disc implant comprising:
a plurality of envelopes filled with a keratin hydrogel; and said plurality of envelopes encased in an envelope.
28. An intervertebral disc implant comprising:
a plurality of envelopes filled with a keratin hydrogel; and said plurality of envelopes connected by passageways such that the keratin hydrogel can be urged from one envelope to another.
29. An annular repair comprising:
a sheet of keratin-based material adapted for repairing a disc annulus.
30. An annular repair comprising:
a plug of keratin-based material adapted for repairing a disc annulus.
31. An annular repair comprising:
keratin-based material deposited on one of woven and non-woven material.
32. The implant of claim 1 wherein said layer includes at least one of chondrocytes, fibrochondrocytes, fibroblasts, osteoblasts, and/or osteocytes.
33. The implant of claim 1 wherein said layer includes bone morphogenetic proteins (BMPs).
34. The implant of claim 19 including at least one of chondrocytes, fibrochondrocytes, fibroblasts, osteoblasts, and/or osteocytes.
35. The implant of claim 19 including bone morphogenetic proteins (BMPs).
36. The implant of claim 29 wherein said sheet includes at least one of chondrocytes, fibrochondrocytes, fibroblasts, osteoblasts, and/or osteocytes.
37. The implant of claim 29 wherein said sheet includes bone morphogenetic proteins (BMPs).
38. The implant of claim 30 wherein said plug includes at least one of chondrocytes, fibrochondrocytes, fibroblasts, osteoblasts, and/or osteocytes.
39. The implant of claim 30 wherein said plug includes bone morphogenetic proteins (BMPs).
40. The implant of claim 19 including a plurality layers with each layer formed of keratin-based material and with each layer having directional different structural properties.
41. The implant of claim 19 at least one of upper and lower layers located adjacent to the disc annulus wherein at least one of the upper and lower layers are formed from keratin-based material.
42. The implant of claim 19 wherein at least one layer is formed of sheets of keratin-based material.
43. The implant of claim 41 wherein at least one of the upper and lower layers is formed of sheets of keratin-based material.
44. The implant of claim 27 wherein at least one of said envelopes is comprised of a keratin-based material.
45. The implant of claim 27 wherein at least one of said envelopes is comprised of a keratin-based material which is part of a non-woven material.
46. The implant of claim 27 wherein at least one of said envelopes is comprised of a keratin-based material which is part of a woven material.
47. The implant of claim 27 wherein at least one of said envelopes is comprised of a plurality of sheets of keratin-based materials.
48. The implant of claim 27 wherein at least one of said envelopes is comprised of a plurality of sheets of keratin-based material with each sheet having directionally different structural properties.
49. The implant of claim 27 wherein at least one of said envelopes has included therein at least one of cells and growth factors.
50. The implant of claim 27 wherein at least one of said envelopes is comprised of a keratin-based material.
51. The implant of claim 28 wherein at least one of said envelopes is comprised of a keratin-based material which is part of a non-woven material.
52. The implant of claim 28 wherein at least one of said envelopes is comprised of a keratin-based material which is part of a woven material.
53. The implant of claim 28 wherein at least one of said envelopes is comprised of a plurality of sheets of keratin-based material.
54. The implant of claim 28 wherein at least one of said envelopes is comprised of a plurality of sheets of keratin-based material with each sheet having directionally different structural properties.
55. The implant of claim 29 including a plurality of sheets of keratin-based material adapted for repairing a disc annulus.
56. A method for repairing or replacing an intervertebral disc including the steps of:
assessing the disc space of a patent;
as necessary removing disc material of the patient;
selecting an implant comprised of a keratin material;
placing the implant in the disc space; and closing.
57. A method for repairing or replacing an intervertebral disc including the steps of:
accessing the disc space of a patient;
as necessary removing disc material of the patient;
selecting an implant comprised of one or more layers of a keratin-based material formed in the shape of a disc annulus and with a keratin-based hydrogel filling the space of the disc annulus;
placing the implant in the disc space; and closing.
58. An intervertebral implant comprising:
a plurality of layers of keratin-based material formed in the shape of at least a partial disc annulus.
59. The implant of claim 58 including:
said layers of defining an internal cavity which has therein at least one of cells and growth factors.
60. A method for repairing or replacing an intervertebral disc including the steps of:
assessing the disc space of a patent;
as necessary removing the disc material of the patient;
selecting an implant comprised of a plurality of envelopes filled with a keratin hydrogel and with the plurality of envelopes encased in an envelope;
placing the implant in the disc space; and closing.
61. A method for repairing or replacing an intervertebral disc including the steps of:
assessing the disc space of a patient;
as necessary removing disc material of the patient;
selecting an implant comprised of a plurality of envelopes filled with a keratin hydrogel and with the plurality of envelopes connected by passageways such that the keratin hydrogel can be urged from one envelope to another;
placing the implant in the disc space; and closing.
62. A method of repairing an annulus including the steps of:
accessing an intervertebral annulus of a patient;
selecting of a keratin-based material;
inserting the keratin-based material at the location of the annulus repair;
securing the keratin-based material in place; and closing.
63. The method of claim 62 wherein said securing step includes using a tether to attach the keratin-based material to a portion of the annulus of the patient.
64. The method of claim 62 wherein said securing step includes suturing the keratin-based material to the annulus of the patient.
65. The method of claim 62 wherein said keratin-based material is in the shape of a plug and wherein said securing step includes pushing a portion of the keratin-based material through an aperture in the annulus of the patient and allowing the force of the nucleus to hold the keratin-based material against the annulus of the patient.
CA002444629A 2001-03-22 2002-03-20 Implantable prosthetic or tissue expanding device Abandoned CA2444629A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/815,387 2001-03-22
US09/815,387 US6783546B2 (en) 1999-09-13 2001-03-22 Implantable prosthetic or tissue expanding device
PCT/US2002/008576 WO2002076336A2 (en) 2001-03-22 2002-03-20 Implantable prosthetic or tissue expanding device

Publications (1)

Publication Number Publication Date
CA2444629A1 true CA2444629A1 (en) 2002-10-03

Family

ID=25217641

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002444629A Abandoned CA2444629A1 (en) 2001-03-22 2002-03-20 Implantable prosthetic or tissue expanding device

Country Status (6)

Country Link
US (1) US6783546B2 (en)
EP (1) EP1383444A4 (en)
JP (1) JP2004526501A (en)
CA (1) CA2444629A1 (en)
NZ (1) NZ528749A (en)
WO (1) WO2002076336A2 (en)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068630A (en) 1997-01-02 2000-05-30 St. Francis Medical Technologies, Inc. Spine distraction implant
US6045551A (en) 1998-02-06 2000-04-04 Bonutti; Peter M. Bone suture
US6746485B1 (en) 1999-02-18 2004-06-08 St. Francis Medical Technologies, Inc. Hair used as a biologic disk, replacement, and/or structure and method
US6368343B1 (en) 2000-03-13 2002-04-09 Peter M. Bonutti Method of using ultrasonic vibration to secure body tissue
US6447516B1 (en) 1999-08-09 2002-09-10 Peter M. Bonutti Method of securing tissue
US6821276B2 (en) * 1999-08-18 2004-11-23 Intrinsic Therapeutics, Inc. Intervertebral diagnostic and manipulation device
US8323341B2 (en) 2007-09-07 2012-12-04 Intrinsic Therapeutics, Inc. Impaction grafting for vertebral fusion
WO2009033100A1 (en) 2007-09-07 2009-03-12 Intrinsic Therapeutics, Inc. Bone anchoring systems
US7717961B2 (en) 1999-08-18 2010-05-18 Intrinsic Therapeutics, Inc. Apparatus delivery in an intervertebral disc
MXPA03003600A (en) 1999-08-18 2004-12-02 Intrinsic Orthopedics Inc Devices and method for nucleus pulposus augmentation and retention.
US7998213B2 (en) 1999-08-18 2011-08-16 Intrinsic Therapeutics, Inc. Intervertebral disc herniation repair
US20040010317A1 (en) * 1999-08-18 2004-01-15 Gregory Lambrecht Devices and method for augmenting a vertebral disc
EP1624832A4 (en) * 1999-08-18 2008-12-24 Intrinsic Therapeutics Inc Devices and method for augmenting a vertebral disc nucleus
US7553329B2 (en) 1999-08-18 2009-06-30 Intrinsic Therapeutics, Inc. Stabilized intervertebral disc barrier
US7972337B2 (en) 2005-12-28 2011-07-05 Intrinsic Therapeutics, Inc. Devices and methods for bone anchoring
US20040044412A1 (en) * 1999-08-18 2004-03-04 Gregory Lambrecht Devices and method for augmenting a vertebral disc
US7220281B2 (en) 1999-08-18 2007-05-22 Intrinsic Therapeutics, Inc. Implant for reinforcing and annulus fibrosis
US6964674B1 (en) * 1999-09-20 2005-11-15 Nuvasive, Inc. Annulotomy closure device
US6264695B1 (en) 1999-09-30 2001-07-24 Replication Medical, Inc. Spinal nucleus implant
US8128698B2 (en) 1999-10-20 2012-03-06 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US7615076B2 (en) 1999-10-20 2009-11-10 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US7052516B2 (en) 1999-10-20 2006-05-30 Anulex Technologies, Inc. Spinal disc annulus reconstruction method and deformable spinal disc annulus stent
US7951201B2 (en) 1999-10-20 2011-05-31 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US6592625B2 (en) * 1999-10-20 2003-07-15 Anulex Technologies, Inc. Spinal disc annulus reconstruction method and spinal disc annulus stent
US7004970B2 (en) 1999-10-20 2006-02-28 Anulex Technologies, Inc. Methods and devices for spinal disc annulus reconstruction and repair
US8632590B2 (en) 1999-10-20 2014-01-21 Anulex Technologies, Inc. Apparatus and methods for the treatment of the intervertebral disc
US7935147B2 (en) * 1999-10-20 2011-05-03 Anulex Technologies, Inc. Method and apparatus for enhanced delivery of treatment device to the intervertebral disc annulus
US20030153976A1 (en) * 1999-10-20 2003-08-14 Cauthen Joseph C. Spinal disc annulus reconstruction method and spinal disc annulus stent
US6635073B2 (en) 2000-05-03 2003-10-21 Peter M. Bonutti Method of securing body tissue
US6899716B2 (en) * 2000-02-16 2005-05-31 Trans1, Inc. Method and apparatus for spinal augmentation
US6740093B2 (en) 2000-02-28 2004-05-25 Stephen Hochschuler Method and apparatus for treating a vertebral body
US7094251B2 (en) 2002-08-27 2006-08-22 Marctec, Llc. Apparatus and method for securing a suture
US9138222B2 (en) 2000-03-13 2015-09-22 P Tech, Llc Method and device for securing body tissue
US9314339B2 (en) * 2000-03-27 2016-04-19 Formae, Inc. Implants for replacing cartilage, with negatively-charged hydrogel surfaces and flexible matrix reinforcement
US6805695B2 (en) 2000-04-04 2004-10-19 Spinalabs, Llc Devices and methods for annular repair of intervertebral discs
US7465321B2 (en) 2001-08-31 2008-12-16 Keratec Limited Production of biopolymer film, fibre, foam and adhesive materials from soluble S-sulfonated keratin derivatives
US6719765B2 (en) 2001-12-03 2004-04-13 Bonutti 2003 Trust-A Magnetic suturing system and method
US7630403B2 (en) * 2002-03-08 2009-12-08 Texas Instruments Incorporated MAC aggregation frame with MSDU and fragment of MSDU
US9155544B2 (en) 2002-03-20 2015-10-13 P Tech, Llc Robotic systems and methods
US20060106462A1 (en) * 2002-04-16 2006-05-18 Tsou Paul M Implant material for minimally invasive spinal interbody fusion surgery
US7001433B2 (en) 2002-05-23 2006-02-21 Pioneer Laboratories, Inc. Artificial intervertebral disc device
US8388684B2 (en) 2002-05-23 2013-03-05 Pioneer Signal Technology, Inc. Artificial disc device
NZ550755A (en) * 2002-06-10 2009-06-26 Keratec Ltd Orthopaedic materials derived from keratin
US20040054414A1 (en) * 2002-09-18 2004-03-18 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
US7744651B2 (en) * 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US7201775B2 (en) * 2002-09-24 2007-04-10 Bogomir Gorensek Stabilizing device for intervertebral disc, and methods thereof
US20050055094A1 (en) * 2002-11-05 2005-03-10 Kuslich Stephen D. Semi-biological intervertebral disc replacement system
CN100394989C (en) * 2002-11-15 2008-06-18 华沙整形外科股份有限公司 Collagen-based materials and methods for augmenting intervertebral discs
WO2004047690A2 (en) * 2002-11-26 2004-06-10 Raymedica, Inc. Prosthetic spinal disc nucleus with elevated swelling rate
BR0316793A (en) * 2002-11-28 2005-11-01 Keratec Ltd Personal Care Formulations Containing Keratin
NL1022023C2 (en) * 2002-11-29 2004-06-03 Dsm Nv Artificial intervertebral disc.
US20040186471A1 (en) * 2002-12-07 2004-09-23 Sdgi Holdings, Inc. Method and apparatus for intervertebral disc expansion
EP1583490B1 (en) * 2003-01-16 2008-12-10 Replication Medical, INC. Hydrogel-based prosthetic device for replacing at least a part of the nucleus of a spinal disc
US20040143327A1 (en) * 2003-01-17 2004-07-22 Ku David N. Solid implant
EP1594421A4 (en) * 2003-01-17 2006-02-08 Psinergi Corp Artificial nucleus pulposus and method of injecting same
US20060015182A1 (en) * 2003-02-25 2006-01-19 Tsou Paul M Patch material for intervertebral disc annulus defect repair
US20040193274A1 (en) * 2003-03-28 2004-09-30 Trieu Hai H. Materials and methods for augmenting and/or repairing intervertebral discs
US7497864B2 (en) 2003-04-30 2009-03-03 Marctec, Llc. Tissue fastener and methods for using same
DK1638485T3 (en) 2003-06-20 2011-05-02 Intrinsic Therapeutics Inc Device for delivery of an implant through an annular defect in an intervertebral disc
US20050015140A1 (en) * 2003-07-14 2005-01-20 Debeer Nicholas Encapsulation device and methods of use
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
US20050055099A1 (en) * 2003-09-09 2005-03-10 Ku David N. Flexible spinal disc
US7767756B2 (en) * 2003-09-19 2010-08-03 Keraplast Technologies, Ltd. Composite materials containing keratin
US7815561B2 (en) 2003-09-25 2010-10-19 Xoft, Inc. Brachytherapy applicator
US20050090899A1 (en) * 2003-10-24 2005-04-28 Dipoto Gene Methods and apparatuses for treating the spine through an access device
EP1523963B1 (en) * 2003-10-17 2007-12-12 Co-Ligne AG Fusion implant
US9445916B2 (en) 2003-10-22 2016-09-20 Pioneer Surgical Technology, Inc. Joint arthroplasty devices having articulating members
US20050119752A1 (en) * 2003-11-19 2005-06-02 Synecor Llc Artificial intervertebral disc
JP4662948B2 (en) * 2003-12-19 2011-03-30 ケラテク リミテッド Wound care products containing keratin
US20050143816A1 (en) * 2003-12-30 2005-06-30 Intellectual Property International, Inc. Implant filling material and method
US7988986B2 (en) * 2003-12-30 2011-08-02 Beisang Arthur A Implant filling material and method
US20060241754A1 (en) * 2003-12-30 2006-10-26 Beisang Arthur A Implant filling material and method
US8084513B2 (en) * 2003-12-30 2011-12-27 Beisang Arthur A Implant filling material and method
US8734525B2 (en) 2003-12-31 2014-05-27 Warsaw Orthopedic, Inc. Osteoinductive demineralized cancellous bone
CA2535169A1 (en) 2003-12-31 2005-07-21 Osteotech, Inc. Improved bone matrix compositions and methods
US20050177245A1 (en) * 2004-02-05 2005-08-11 Leatherbury Neil C. Absorbable orthopedic implants
WO2005077013A2 (en) 2004-02-06 2005-08-25 Georgia Tech Research Corporation Surface directed cellular attachment
CA2558661C (en) 2004-02-06 2012-09-04 Georgia Tech Research Corporation Load bearing biocompatible device
US20080039873A1 (en) 2004-03-09 2008-02-14 Marctec, Llc. Method and device for securing body tissue
US20050209602A1 (en) * 2004-03-22 2005-09-22 Disc Dynamics, Inc. Multi-stage biomaterial injection system for spinal implants
US20060135959A1 (en) * 2004-03-22 2006-06-22 Disc Dynamics, Inc. Nuclectomy method and apparatus
US20050273172A1 (en) * 2004-06-07 2005-12-08 Patil Arun A Artificial disc and uses therefor
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
US8128662B2 (en) 2004-10-20 2012-03-06 Vertiflex, Inc. Minimally invasive tooling for delivery of interspinous spacer
US8012207B2 (en) * 2004-10-20 2011-09-06 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US7763074B2 (en) 2004-10-20 2010-07-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8425559B2 (en) 2004-10-20 2013-04-23 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8613747B2 (en) 2004-10-20 2013-12-24 Vertiflex, Inc. Spacer insertion instrument
US8945183B2 (en) * 2004-10-20 2015-02-03 Vertiflex, Inc. Interspinous process spacer instrument system with deployment indicator
US9161783B2 (en) 2004-10-20 2015-10-20 Vertiflex, Inc. Interspinous spacer
US8152837B2 (en) 2004-10-20 2012-04-10 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8409282B2 (en) 2004-10-20 2013-04-02 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8123807B2 (en) * 2004-10-20 2012-02-28 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8123782B2 (en) 2004-10-20 2012-02-28 Vertiflex, Inc. Interspinous spacer
WO2009009049A2 (en) 2004-10-20 2009-01-15 Vertiflex, Inc. Interspinous spacer
US8277488B2 (en) 2004-10-20 2012-10-02 Vertiflex, Inc. Interspinous spacer
US8317864B2 (en) 2004-10-20 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US9023084B2 (en) 2004-10-20 2015-05-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for stabilizing the motion or adjusting the position of the spine
US9119680B2 (en) 2004-10-20 2015-09-01 Vertiflex, Inc. Interspinous spacer
US8167944B2 (en) 2004-10-20 2012-05-01 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US20060089646A1 (en) 2004-10-26 2006-04-27 Bonutti Peter M Devices and methods for stabilizing tissue and implants
US9271766B2 (en) 2004-10-26 2016-03-01 P Tech, Llc Devices and methods for stabilizing tissue and implants
US9463012B2 (en) 2004-10-26 2016-10-11 P Tech, Llc Apparatus for guiding and positioning an implant
US9173647B2 (en) 2004-10-26 2015-11-03 P Tech, Llc Tissue fixation system
WO2009086010A2 (en) 2004-12-06 2009-07-09 Vertiflex, Inc. Spacer insertion instrument
US20090264939A9 (en) * 2004-12-16 2009-10-22 Martz Erik O Instrument set and method for performing spinal nuclectomy
US9089323B2 (en) 2005-02-22 2015-07-28 P Tech, Llc Device and method for securing body tissue
JP2008531769A (en) * 2005-02-23 2008-08-14 ズィマー・テクノロジー・インコーポレーテッド Blend hydrogel and method for producing the same
US7579317B2 (en) * 2005-03-11 2009-08-25 Keratec, Ltd. Nutraceutical composition comprising soluble keratin or derivative thereof
US20060224244A1 (en) * 2005-03-31 2006-10-05 Zimmer Technology, Inc. Hydrogel implant
US7879103B2 (en) * 2005-04-15 2011-02-01 Musculoskeletal Transplant Foundation Vertebral disc repair
US7182783B2 (en) * 2005-04-25 2007-02-27 Sdgi Holdings, Inc. Selectively expandable composite structures for spinal arthroplasty
US20060253198A1 (en) * 2005-05-03 2006-11-09 Disc Dynamics, Inc. Multi-lumen mold for intervertebral prosthesis and method of using same
US20060253199A1 (en) * 2005-05-03 2006-11-09 Disc Dynamics, Inc. Lordosis creating nucleus replacement method and apparatus
US20090105826A1 (en) * 2005-06-03 2009-04-23 Mcleod Alan Surgical Implants
US7988735B2 (en) * 2005-06-15 2011-08-02 Matthew Yurek Mechanical apparatus and method for delivering materials into the inter-vertebral body space for nucleus replacement
US7799087B2 (en) * 2005-08-31 2010-09-21 Zimmer Gmbh Implant
US20070073397A1 (en) * 2005-09-15 2007-03-29 Mckinley Laurence M Disc nucleus prosthesis and its method of insertion and revision
US8920827B2 (en) 2005-10-21 2014-12-30 Wake Forest University Health Sciences Keratin bioceramic compositions
US7914578B2 (en) * 2005-10-24 2011-03-29 Gil Vardi Method and apparatus for expanding tissue
US8911759B2 (en) 2005-11-01 2014-12-16 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8403985B2 (en) * 2005-11-02 2013-03-26 Zimmer, Inc. Joint spacer implant
US8308807B2 (en) 2005-11-09 2012-11-13 Zimmer, Gmbh Implant with differential anchoring
EP1954215A4 (en) * 2005-11-21 2012-12-19 Nicast Ltd Spinal nucleus prosthesis device
WO2007062080A2 (en) * 2005-11-21 2007-05-31 Philipp Lang Intervetebral devices and methods
AU2006321809A1 (en) * 2005-12-07 2007-06-14 Zimmer, Inc. Methods of bonding or modifying hydrogels using irradiation
US8017107B2 (en) 2005-12-22 2011-09-13 Zimmer, Inc. Perfluorocyclobutane crosslinked hydrogels
AU2006332156B2 (en) * 2005-12-23 2012-07-05 Zimmer Gmbh Coated textiles
US8506633B2 (en) * 2005-12-27 2013-08-13 Warsaw Orthopedic, Inc. Rehydration and restoration of intervertebral discs with polyelectrolytes
US8801790B2 (en) * 2005-12-27 2014-08-12 Warsaw Orthopedic, Inc. Intervertebral disc augmentation and rehydration with superabsorbent polymers
US20070179607A1 (en) * 2006-01-31 2007-08-02 Zimmer Technology, Inc. Cartilage resurfacing implant
US20070191848A1 (en) * 2006-02-01 2007-08-16 Zimmer Technology, Inc. Hydrogel bone plate spacer
US11253296B2 (en) 2006-02-07 2022-02-22 P Tech, Llc Methods and devices for intracorporeal bonding of implants with thermal energy
US7967820B2 (en) 2006-02-07 2011-06-28 P Tech, Llc. Methods and devices for trauma welding
US8496657B2 (en) 2006-02-07 2013-07-30 P Tech, Llc. Methods for utilizing vibratory energy to weld, stake and/or remove implants
ES2614510T3 (en) * 2006-02-07 2017-05-31 Spinalcyte, Llc Method and compositions for cartilage repair using an in vivo bioreactor
US11278331B2 (en) 2006-02-07 2022-03-22 P Tech Llc Method and devices for intracorporeal bonding of implants with thermal energy
US8273702B2 (en) * 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US20070270950A1 (en) * 2006-02-17 2007-11-22 Sdgi Holdings, Inc. Partial intervertebral implant and method of augmenting a disc surgery
AU2007217898A1 (en) * 2006-02-17 2007-08-30 Wake Forest University Health Sciences Coatings and biomedical implants formed from keratin biomaterials
US7918889B2 (en) * 2006-02-27 2011-04-05 Warsaw Orthopedic, Inc. Expandable spinal prosthetic devices and associated methods
US8110242B2 (en) 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
US20070233245A1 (en) * 2006-03-31 2007-10-04 Sdgi Holdings, Inc. Methods and instruments for delivering intervertebral devices
US7771414B2 (en) * 2006-04-24 2010-08-10 Warsaw Orthopedic, Inc. Controlled release devices for therapeutic treatments of spinal discs
US8642060B2 (en) * 2006-04-24 2014-02-04 Warsaw Orthopedic, Inc. Controlled release systems and methods for osteal growth
US8642059B2 (en) * 2006-04-24 2014-02-04 Warsaw Orthopedic, Inc. Controlled release systems and methods for intervertebral discs
US7879027B2 (en) * 2006-04-24 2011-02-01 Warsaw Orthopedic, Inc. Controlled release devices for fusion of osteal structures
US20070255286A1 (en) * 2006-04-27 2007-11-01 Sdgi Holdings, Inc. Devices, apparatus, and methods for improved disc augmentation
US8133279B2 (en) * 2006-04-27 2012-03-13 Warsaw Orthopedic, Inc. Methods for treating an annulus defect of an intervertebral disc
US20070255406A1 (en) * 2006-04-27 2007-11-01 Sdgi Holdings, Inc. Devices, apparatus, and methods for bilateral approach to disc augmentation
EP2019653B1 (en) * 2006-04-28 2016-11-16 The University of Hong Kong Bioengineered intervertebral discs and methods for their preparation
WO2007125060A1 (en) 2006-04-28 2007-11-08 Zimmer Gmbh Implant
US11246638B2 (en) 2006-05-03 2022-02-15 P Tech, Llc Methods and devices for utilizing bondable materials
US8399619B2 (en) * 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8118779B2 (en) * 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US20080004703A1 (en) * 2006-06-30 2008-01-03 Warsaw Orthopedic, Inc. Method of treating a patient using a collagen material
US20080004431A1 (en) * 2006-06-30 2008-01-03 Warsaw Orthopedic Inc Method of manufacturing an injectable collagen material
US20080058931A1 (en) * 2006-07-21 2008-03-06 John White Expandable vertebral implant and methods of use
EP2076220A2 (en) 2006-07-25 2009-07-08 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
US7758649B2 (en) * 2006-08-04 2010-07-20 Integrity Intellect Inc. Reversibly deformable implant
US8715350B2 (en) 2006-09-15 2014-05-06 Pioneer Surgical Technology, Inc. Systems and methods for securing an implant in intervertebral space
US8900306B2 (en) * 2006-09-26 2014-12-02 DePuy Synthes Products, LLC Nucleus anti-expulsion devices and methods
US20080082170A1 (en) * 2006-09-29 2008-04-03 Peterman Marc M Apparatus and methods for surgical repair
US8066750B2 (en) 2006-10-06 2011-11-29 Warsaw Orthopedic, Inc Port structures for non-rigid bone plates
US8845726B2 (en) 2006-10-18 2014-09-30 Vertiflex, Inc. Dilator
US20080107711A1 (en) * 2006-11-08 2008-05-08 Alexis Paul Shelokov Bioabsorbable Implantable Material Fortified with Antibiotics for Localized Delivery of Drugs
ES2515118T3 (en) * 2006-12-06 2014-10-29 Keratec Limited Fillers for bone gaps and their manufacturing procedures
WO2008073376A2 (en) * 2006-12-11 2008-06-19 Keratec, Ltd. Porous keratin construct and method of making the same
US20080177389A1 (en) * 2006-12-21 2008-07-24 Rob Gene Parrish Intervertebral disc spacer
US20080234822A1 (en) * 2007-01-26 2008-09-25 Tutogen Medical, U.S., Inc. Method and Apparatus for Stabilization and Fusion of Adjacent Bone Segments
CA2618125A1 (en) * 2007-02-08 2008-08-08 Zimmer, Inc. Hydrogel proximal interphalangeal implant
US8617185B2 (en) 2007-02-13 2013-12-31 P Tech, Llc. Fixation device
EP2155121B1 (en) 2007-04-16 2015-06-17 Vertiflex, Inc. Interspinous spacer
US8075593B2 (en) * 2007-05-01 2011-12-13 Spinal Simplicity Llc Interspinous implants and methods for implanting same
US8142479B2 (en) * 2007-05-01 2012-03-27 Spinal Simplicity Llc Interspinous process implants having deployable engagement arms
WO2008148109A1 (en) * 2007-05-24 2008-12-04 Keratec, Ltd. Porous keratin constructs, wound healing assemblies and methods using the same
US20080300684A1 (en) * 2007-05-31 2008-12-04 Shelokov Alexis P System and method for controlled delivery of bone morphogenic protein and other bone graft substitutes for bone formation, repair and healing
WO2008157497A2 (en) 2007-06-15 2008-12-24 Osteotech, Inc. Method of treating tissue
US9554920B2 (en) 2007-06-15 2017-01-31 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
CA2690457C (en) 2007-06-15 2018-02-20 Osteotech, Inc. Bone matrix compositions and methods
US9492278B2 (en) 2007-07-10 2016-11-15 Warsaw Orthopedic, Inc. Delivery system
US8979935B2 (en) 2007-07-31 2015-03-17 Zimmer, Inc. Joint space interpositional prosthetic device with internal bearing surfaces
US7731988B2 (en) * 2007-08-03 2010-06-08 Zimmer, Inc. Multi-polymer hydrogels
US20090047260A1 (en) * 2007-08-17 2009-02-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
US8062739B2 (en) 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
US8308767B2 (en) 2007-09-19 2012-11-13 Pioneer Surgical Technology, Inc. Interlaminar stabilization system
WO2009052492A2 (en) 2007-10-19 2009-04-23 Osteotech, Inc. Demineralized bone matrix compositions and methods
MX2010004687A (en) * 2007-10-31 2011-03-01 Keraplast Tech Ltd Keratin derivatives and methods of making the same.
US20090112332A1 (en) * 2007-10-31 2009-04-30 Alexis Paul Shelokov Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery
US7947784B2 (en) 2007-11-16 2011-05-24 Zimmer, Inc. Reactive compounding of hydrogels
US8034362B2 (en) 2008-01-04 2011-10-11 Zimmer, Inc. Chemical composition of hydrogels for use as articulating surfaces
WO2009091922A2 (en) 2008-01-15 2009-07-23 Vertiflex, Inc. Interspinous spacer
US20090222096A1 (en) * 2008-02-28 2009-09-03 Warsaw Orthopedic, Inc. Multi-compartment expandable devices and methods for intervertebral disc expansion and augmentation
US20090326657A1 (en) * 2008-06-25 2009-12-31 Alexander Grinberg Pliable Artificial Disc Endplate
US9808345B2 (en) * 2008-07-24 2017-11-07 Iorthopedics, Inc. Resilient arthroplasty device
EP2326281A4 (en) * 2008-08-13 2013-05-29 Smed Ta Td Llc Orthopaedic implant with porous structural member
US20100042213A1 (en) 2008-08-13 2010-02-18 Nebosky Paul S Drug delivery implants
US9700431B2 (en) 2008-08-13 2017-07-11 Smed-Ta/Td, Llc Orthopaedic implant with porous structural member
US8475505B2 (en) * 2008-08-13 2013-07-02 Smed-Ta/Td, Llc Orthopaedic screws
US10842645B2 (en) 2008-08-13 2020-11-24 Smed-Ta/Td, Llc Orthopaedic implant with porous structural member
US9616205B2 (en) 2008-08-13 2017-04-11 Smed-Ta/Td, Llc Drug delivery implants
EP2341852B1 (en) 2008-08-29 2018-08-15 SMed-TA/TD, LLC Orthopaedic implant
US8163022B2 (en) 2008-10-14 2012-04-24 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
WO2010093950A1 (en) * 2009-02-12 2010-08-19 Osteotech, Inc. Delivery system cartridge
WO2010093882A1 (en) * 2009-02-13 2010-08-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
EP2400899A4 (en) 2009-02-24 2015-03-18 P Tech Llc Methods and devices for utilizing bondable materials
WO2010100267A1 (en) * 2009-03-05 2010-09-10 Dsm Ip Assets B.V. Spinal fusion cage
US8945184B2 (en) * 2009-03-13 2015-02-03 Spinal Simplicity Llc. Interspinous process implant and fusion cage spacer
US9861399B2 (en) 2009-03-13 2018-01-09 Spinal Simplicity, Llc Interspinous process implant having a body with a removable end portion
US9757164B2 (en) 2013-01-07 2017-09-12 Spinal Simplicity Llc Interspinous process implant having deployable anchor blades
JP2012526845A (en) * 2009-05-13 2012-11-01 ケラプラスト テクノロジーズ, リミテッド Biopolymer material
US9132207B2 (en) * 2009-10-27 2015-09-15 Spine Wave, Inc. Radiopaque injectable nucleus hydrogel compositions
US8740948B2 (en) 2009-12-15 2014-06-03 Vertiflex, Inc. Spinal spacer for cervical and other vertebra, and associated systems and methods
US8460319B2 (en) 2010-01-11 2013-06-11 Anulex Technologies, Inc. Intervertebral disc annulus repair system and method
US10307257B2 (en) 2010-01-22 2019-06-04 Iorthopedics, Inc. Resilient knee implant and methods
WO2011091005A2 (en) 2010-01-22 2011-07-28 Grotz R Thomas Resilient knee implant and methods
US20110295370A1 (en) * 2010-06-01 2011-12-01 Sean Suh Spinal Implants and Methods of Use Thereof
US8668739B2 (en) 2010-08-20 2014-03-11 Zimmer, Inc. Unitary orthopedic implant
EP2640408B1 (en) 2010-11-17 2016-05-25 Wake Forest University Health Sciences Keratin compositions for treatment of bone deficiency or injury
US9757241B2 (en) 2011-09-01 2017-09-12 R. Thomas Grotz Resilient interpositional arthroplasty device
USD833613S1 (en) 2011-01-19 2018-11-13 Iorthopedics, Inc. Resilient knee implant
US9700425B1 (en) 2011-03-20 2017-07-11 Nuvasive, Inc. Vertebral body replacement and insertion methods
US20120276008A1 (en) * 2011-04-26 2012-11-01 Spine Wave, Inc. Radiopaque injectable nucleus hydrogel compositions
CA3048437C (en) 2011-05-26 2022-06-21 Cartiva, Inc. Tapered joint implant and related tools
WO2013025941A1 (en) 2011-08-17 2013-02-21 Keranetics Llc Low protein percentage gelling compositions
EP2744820B1 (en) 2011-08-17 2018-07-25 Keranetics LLC Methods for extracting keratin proteins
US9198769B2 (en) 2011-12-23 2015-12-01 Pioneer Surgical Technology, Inc. Bone anchor assembly, bone plate system, and method
US20130282121A1 (en) * 2012-03-22 2013-10-24 Ann Prewett Spinal facet augmentation implant and method
US9307968B2 (en) * 2012-06-15 2016-04-12 The University Of Hong Kong Materials and methods for filling biological cavities and preventing leakage of injected therapeutic agents
US9498335B2 (en) * 2012-10-02 2016-11-22 Seth McCullen Implantable devices for musculoskeletal repair and regeneration
US10820984B2 (en) 2012-11-14 2020-11-03 ImplantADJUST, LLC Implant with elastomeric membrane and methods of fabrication thereof
US9351824B2 (en) 2012-11-14 2016-05-31 ImplantADJUST, LLC Adjustable implant with self-sealing elastomeric membrane and methods of fabrication thereof
US10076377B2 (en) 2013-01-05 2018-09-18 P Tech, Llc Fixation systems and methods
US10070969B2 (en) 2013-01-17 2018-09-11 Stryker European Holdings I, Llc Annulus plug for intervertebral disc repair
US9737294B2 (en) 2013-01-28 2017-08-22 Cartiva, Inc. Method and system for orthopedic repair
AU2014209124A1 (en) 2013-01-28 2015-09-17 Cartiva, Inc. Systems and methods for orthopedic repair
US9408699B2 (en) 2013-03-15 2016-08-09 Smed-Ta/Td, Llc Removable augment for medical implant
US9681966B2 (en) 2013-03-15 2017-06-20 Smed-Ta/Td, Llc Method of manufacturing a tubular medical implant
US9724203B2 (en) 2013-03-15 2017-08-08 Smed-Ta/Td, Llc Porous tissue ingrowth structure
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone
US9675303B2 (en) 2013-03-15 2017-06-13 Vertiflex, Inc. Visualization systems, instruments and methods of using the same in spinal decompression procedures
US10206954B2 (en) 2013-06-19 2019-02-19 Spinalcyte, Llc Adipose cells for chondrocyte applications
CN103393481B (en) * 2013-08-07 2015-08-12 邹德宏 For conformal prosthese after mammary gland excalation and preparation method thereof
AU2015256024B2 (en) 2014-05-07 2020-03-05 Vertiflex, Inc. Spinal nerve decompression systems, dilation systems, and methods of using the same
EP3200728B1 (en) 2014-10-02 2019-08-07 McCullen, Seth Anatomically designed meniscus implantable devices
WO2016161025A1 (en) 2015-03-31 2016-10-06 Cartiva, Inc. Hydrogel implants with porous materials and methods
EP3636226A1 (en) 2015-03-31 2020-04-15 Cartiva, Inc. Carpometacarpal (cmc) implants
WO2016168363A1 (en) 2015-04-14 2016-10-20 Cartiva, Inc. Tooling for creating tapered opening in tissue and related methods
US10064736B2 (en) * 2015-06-25 2018-09-04 University of Central Oklahoma Engineered intervertebral disc (IVD) for degenerated disc disease
US10058393B2 (en) 2015-10-21 2018-08-28 P Tech, Llc Systems and methods for navigation and visualization
US11452606B2 (en) 2017-05-02 2022-09-27 Orthonika Limited Composite joint implant
AU2018327353A1 (en) 2017-09-08 2020-03-19 Pioneer Surgical Technology, Inc. Intervertebral implants, instruments, and methods
USD907771S1 (en) 2017-10-09 2021-01-12 Pioneer Surgical Technology, Inc. Intervertebral implant
KR102206827B1 (en) * 2020-04-03 2021-01-22 손정완 Prosthetic device using high strength hydrogel

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US922692A (en) 1907-10-07 1909-05-25 Byron B Goldsmith Thermoplastic keratin composition.
US926999A (en) 1907-11-25 1909-07-06 Carl Neuberg Process of producing digestible substances from keratin.
US960914A (en) 1909-09-21 1910-06-07 Arthur Heinemann Pills for the treatment of diabetes mellitus.
US1214299A (en) 1915-06-30 1917-01-30 William M Grosvenor Manufacturing colloids.
IT377232A (en) 1938-08-26 1900-01-01
US2434688A (en) 1942-11-03 1948-01-20 Ralph L Evans Regenerated keratin
US2447860A (en) 1944-11-07 1948-08-24 Us Agriculture Method of dispersing keratin proteins and the composition resulting therefrom
US2517572A (en) 1948-11-23 1950-08-08 Chase B Jones Process of utilizing detergents to solubilize keratin materials
US2814851A (en) 1953-12-11 1957-12-03 Rubberset Company Keratin treating process and products thereof
US3033755A (en) 1961-04-14 1962-05-08 Kolmar Laboratories Process for removing the water soluble materials from a keratin structure and cosmetic or pharmaceutical product formed therefrom
US3655416A (en) 1968-12-18 1972-04-11 Lever Brothers Ltd Lipid-protein membrane and process
CS148810B1 (en) 1969-06-13 1973-05-24
US3642498A (en) 1969-09-18 1972-02-15 Gen Mills Inc Method of preparing keratin-containing films and coatings
US4172823A (en) 1970-03-26 1979-10-30 Ceskoslovenska Akademie Ved Method of preparing cross-linked hydrogels
US4123406A (en) 1970-03-26 1978-10-31 Ceskoslovenska Akademie Ved Method of preparing shaped articles from cross-linked hydrogels
CA992255A (en) 1971-01-25 1976-07-06 Cutter Laboratories Prosthesis for spinal repair
US4183884A (en) 1973-01-24 1980-01-15 Ceskoslovenska Akademie Ved Method for manufacturing hydrogel tubes
CS164542B1 (en) 1973-02-15 1975-11-07
US4178361A (en) 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
CS173836B1 (en) 1974-03-19 1977-03-31
CS169274B1 (en) 1974-03-29 1976-07-29
US3875595A (en) 1974-04-15 1975-04-08 Edward C Froning Intervertebral disc prosthesis and instruments for locating same
CS179567B1 (en) 1974-11-25 1977-11-30 Vladimir Stoy Ionogennic hydrophilic in water insoluble gels based on partial saponificated polymers or copolymers acrylonitrile and method of preparing them
JPS537760A (en) 1976-07-12 1978-01-24 Agency Of Ind Science & Technol Modified keratin membrane
CA1146301A (en) 1980-06-13 1983-05-17 J. David Kuntz Intervertebral disc prosthesis
US4309777A (en) 1980-11-13 1982-01-12 Patil Arun A Artificial intervertebral disc
JPS599600B2 (en) 1980-11-14 1984-03-03 花王株式会社 Shampoo - Composition
JPS5785308A (en) 1980-11-17 1982-05-28 Kao Corp Hair rinse composition
US4369037A (en) 1980-11-19 1983-01-18 Kao Soap Co., Ltd. Hair treatment cosmetics containing cationic keratin derivatives
JPS5791910A (en) 1980-11-28 1982-06-08 Kao Corp Preshampoo-type hair treatment composition
JPS57130910A (en) 1981-02-05 1982-08-13 Kao Corp Hair treatment agent
JPS57144213A (en) 1981-03-03 1982-09-06 Kao Corp Hair treatment
US4357274A (en) 1981-08-06 1982-11-02 Intermedicat Gmbh Process for the manufacture of sclero protein transplants with increased biological stability
US4570629A (en) 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
DE3470457D1 (en) 1983-02-25 1988-05-26 Kao Corp Hair cosmetics
LU85081A1 (en) 1983-11-09 1985-07-17 Oreal DRUG AND DRUG COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF SKIN DISEASES INVOLVING AN INFLAMMATORY PROCESS
US4685447A (en) 1985-03-25 1987-08-11 Pmt Corporation Tissue expander system
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US4766005A (en) 1986-10-30 1988-08-23 Opi Products, Inc. Material and method for obtaining strong adhesive bonding to proteinaceous substrates
CH671691A5 (en) * 1987-01-08 1989-09-29 Sulzer Ag
US4714469A (en) 1987-02-26 1987-12-22 Pfizer Hospital Products Group, Inc. Spinal implant
US5108438A (en) * 1989-03-02 1992-04-28 Regen Corporation Prosthetic intervertebral disc
US5258043A (en) 1987-07-20 1993-11-02 Regen Corporation Method for making a prosthetic intervertebral disc
GB8718627D0 (en) 1987-08-06 1987-09-09 Showell A W Sugicraft Ltd Spinal implants
US4772287A (en) 1987-08-20 1988-09-20 Cedar Surgical, Inc. Prosthetic disc and method of implanting
JPH01136655A (en) 1987-11-24 1989-05-29 Asahi Optical Co Ltd Movable type pyramid spacer
US4874389A (en) 1987-12-07 1989-10-17 Downey Ernest L Replacement disc
US4837379A (en) 1988-06-02 1989-06-06 Organogenesis Inc. Fibrin-collagen tissue equivalents and methods for preparation thereof
US4911718A (en) 1988-06-10 1990-03-27 University Of Medicine & Dentistry Of N.J. Functional and biocompatible intervertebral disc spacer
US5484437A (en) 1988-06-13 1996-01-16 Michelson; Gary K. Apparatus and method of inserting spinal implants
US5047249A (en) 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
FR2639958B1 (en) 1988-12-06 1992-08-21 Lille Transfusion Sanguine BIOLOGICAL SUPPORT FOR CELL CULTURES CONSISTING OF PLASMATIC PROTEINS COAGULATED BY THROMBIN, ITS USE FOR THE CULTURE OF KERATINOCYTES, THEIR RECOVERY AND THEIR TRANSPORT FOR THERAPEUTIC USE
ES2153816T3 (en) 1989-01-31 2001-03-16 Jeffrey S Rubin DNA CODING A SPECIFIC GROWTH FACTOR AGAINST EPITHELIAL CELLS.
US4969888A (en) 1989-02-09 1990-11-13 Arie Scholten Surgical protocol for fixation of osteoporotic bone using inflatable device
DE3922203C1 (en) 1989-07-06 1990-10-25 Martin Nolde Surgical instrument for the implantation of an intervertebral disc core prosthesis
US4936848A (en) 1989-09-22 1990-06-26 Bagby George W Implant for vertebrae
US5059193A (en) 1989-11-20 1991-10-22 Spine-Tech, Inc. Expandable spinal implant and surgical method
FR2661414B1 (en) 1990-04-25 1995-03-24 Michel Jean Pierre PRODUCT BASED ON MODIFIED KERATINS, ITS PREPARATION PROCESS AND ITS APPLICATIONS IN PARTICULAR IN HUMAN OR VETERINARY MEDICINE.
EP0453624B1 (en) 1990-04-25 1999-01-13 Descente Ltd. Highly moisture-absorptive fiber
CN1056986A (en) 1990-05-28 1991-12-18 郭素华 Utilize animal wool to produce Keratin sulfate and method of purification thereof
JPH0482561A (en) 1990-07-26 1992-03-16 Niigata High Supinaa Kk Wound cover material
US5292362A (en) 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5276138A (en) 1990-09-17 1994-01-04 Kurashiki Boseki Kabushiki Kaisha Process for solubilizing animal hair
US5047055A (en) 1990-12-21 1991-09-10 Pfizer Hospital Products Group, Inc. Hydrogel intervertebral disc nucleus
US5192326A (en) 1990-12-21 1993-03-09 Pfizer Hospital Products Group, Inc. Hydrogel bead intervertebral disc nucleus
US5123926A (en) 1991-02-22 1992-06-23 Madhavan Pisharodi Artificial spinal prosthesis
US5390683A (en) 1991-02-22 1995-02-21 Pisharodi; Madhavan Spinal implantation methods utilizing a middle expandable implant
JP3007903B2 (en) 1991-03-29 2000-02-14 京セラ株式会社 Artificial disc
US5549672A (en) 1991-12-26 1996-08-27 Mentor Corporation Method and apparatus for filling mammary prostheses and tissue expanders
US5902272A (en) 1992-01-07 1999-05-11 Arthrocare Corporation Planar ablation probe and method for electrosurgical cutting and ablation
US5824331A (en) 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5914265A (en) 1992-04-30 1999-06-22 Baylor College Of Medicine Keratin K1 expression vectors and methods of use
JP3138838B2 (en) 1992-04-30 2001-02-26 東レ・ダウコーニング・シリコーン株式会社 Manufacturing method of mixed powder
US5306309A (en) 1992-05-04 1994-04-26 Calcitek, Inc. Spinal disk implant and implantation kit
DE4222763A1 (en) 1992-07-10 1994-01-13 Draenert Klaus Implant and method for its manufacture
GB9217578D0 (en) 1992-08-19 1992-09-30 Surgicarft Ltd Surgical implants,etc
US5589451A (en) 1992-09-21 1996-12-31 Board Of Regents, The University Of Texas System Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
US5703047A (en) 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5358935A (en) 1992-11-19 1994-10-25 Robert Allen Smith Nonantigenic keratinous protein material
JPH06178787A (en) 1992-12-14 1994-06-28 Shima Yumiko Centrum spacer with joint, intervertebral cavity measuring device and centrum spacer pattern
US5552452A (en) 1993-03-15 1996-09-03 Arch Development Corp. Organic tissue glue for closure of wounds
CA2119064A1 (en) 1993-03-17 1994-09-18 Richard A. Berg Dermal-epidermal in vitro test system
US5660857A (en) 1993-03-22 1997-08-26 Johnson & Johnson Medical Inc. Biopolymer composites
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US5534028A (en) 1993-04-20 1996-07-09 Howmedica, Inc. Hydrogel intervertebral disc nucleus with diminished lateral bulging
CN1105029A (en) 1993-05-24 1995-07-12 花王株式会社 Process for producing solubilized protein
US5480430A (en) 1993-06-04 1996-01-02 Mcghan Medical Corporation Shape-retaining shell for a fluid filled prosthesis
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
SE9302183D0 (en) 1993-06-23 1993-06-23 Radi Medical Systems Ab APPARATUS AND METHOD FOR VIVO MONITORING OF PHYSIOLOGICAL PRESSURES
US5522898A (en) 1993-09-16 1996-06-04 Howmedica Inc. Dehydration of hydrogels
BE1007549A3 (en) 1993-09-21 1995-08-01 Beckers Louis Francois Charles Implant.
US5443514A (en) 1993-10-01 1995-08-22 Acromed Corporation Method for using spinal implants
CN1156255C (en) 1993-10-01 2004-07-07 美商-艾克罗米德公司 Spinal implant
US5514180A (en) 1994-01-14 1996-05-07 Heggeness; Michael H. Prosthetic intervertebral devices
AU1870495A (en) 1994-02-04 1995-08-21 University Of Southern California Method for preventing keratocyte loss
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5571189A (en) 1994-05-20 1996-11-05 Kuslich; Stephen D. Expandable fabric implant for stabilizing the spinal motion segment
JP3338975B2 (en) 1994-06-07 2002-10-28 博史 北條 Keratin fiber modification method
FR2722100B1 (en) 1994-07-11 1996-08-23 Oreal PERVENCHE SEED EXTRACT AND COMPOSITION CONTAINING SAME
EP0700671B1 (en) 1994-09-08 2001-08-08 Stryker Technologies Corporation Hydrogel intervertebral disc nucleus
US5824093A (en) 1994-10-17 1998-10-20 Raymedica, Inc. Prosthetic spinal disc nucleus
DE69532856T2 (en) 1994-10-17 2005-04-21 Raymedica Inc Spinal disc-GRAFT
US5562736A (en) 1994-10-17 1996-10-08 Raymedica, Inc. Method for surgical implantation of a prosthetic spinal disc nucleus
US5674296A (en) 1994-11-14 1997-10-07 Spinal Dynamics Corporation Human spinal disc prosthesis
FR2728159B1 (en) 1994-12-16 1997-06-27 Tornier Sa ELASTIC DISC PROSTHESIS
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5632774A (en) 1995-01-17 1997-05-27 Babian; Hamik In-the-shell hydration to make implant filler material and prosthesis employing same
US5766252A (en) 1995-01-24 1998-06-16 Osteonics Corp. Interbody spinal prosthetic implant and method
DE19504867C1 (en) 1995-02-14 1996-02-29 Harms Juergen Position retainer for spine
US5634945A (en) 1995-03-02 1997-06-03 Pernia; Luis R. Biological filler and use of same
GB9506926D0 (en) 1995-04-04 1995-05-24 Croda Int Plc Cystine-siicone copolymers and their use for treating keratin substrates
IT1281870B1 (en) 1995-04-27 1998-03-03 Fidia Advanced Biopolymers Srl HUMAN ARTIFICIAL SKIN MADE UP OF BIOCOMPATIBLE MATERIALS BASED ON HYALURONIC ACID DERIVATIVES
US5705780A (en) 1995-06-02 1998-01-06 Howmedica Inc. Dehydration of hydrogels
CA2224253A1 (en) 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
US5792090A (en) 1995-06-15 1998-08-11 Ladin; Daniel Oxygen generating wound dressing
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
DK2111876T3 (en) * 1995-12-18 2011-12-12 Angiodevice Internat Gmbh Crosslinked polymer preparations and methods for their use
US5645597A (en) 1995-12-29 1997-07-08 Krapiva; Pavel I. Disc replacement method and apparatus
FR2742987B1 (en) 1996-01-03 1998-04-03 Lvmh Rech USE IN THE FIELD OF COSMETICS AND PHARMACY, ESPECIALLY DERMATOLOGY, OF AN EXTRACT OF ERIOBOTRYA JAPONICA TO STIMULATE THE SYNTHESIS OF GLYCOSAMINOGLYCANS
US5842477A (en) 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
US5916565A (en) 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
US5712252A (en) 1996-03-08 1998-01-27 The University Of Tennessee Research Corporation Method of augmenting soft tissue in mammals
US5791352A (en) 1996-06-19 1998-08-11 Fusion Medical Technologies, Inc. Methods and compositions for inhibiting tissue adhesion
US6110891A (en) 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
US5702455A (en) 1996-07-03 1997-12-30 Saggar; Rahul Expandable prosthesis for spinal fusion
US6008013A (en) 1996-07-05 1999-12-28 University Of Rochester Chondrocyte proteins
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5782831A (en) 1996-11-06 1998-07-21 Sdgi Holdings, Inc. Method an device for spinal deformity reduction using a cable and a cable tensioning system
US5827328A (en) 1996-11-22 1998-10-27 Buttermann; Glenn R. Intervertebral prosthetic device
US6004323A (en) 1997-02-04 1999-12-21 The University Of Iowa Research Foundation Surgically implantable fastening system
US5800549A (en) 1997-04-30 1998-09-01 Howmedica Inc. Method and apparatus for injecting an elastic spinal implant
US6022376A (en) 1997-06-06 2000-02-08 Raymedica, Inc. Percutaneous prosthetic spinal disc nucleus and method of manufacture
GB9713330D0 (en) 1997-06-25 1997-08-27 Bridport Gundry Plc Surgical implant
WO1999004720A1 (en) * 1997-07-11 1999-02-04 Reprogenesis Inc. Repair of intervertebral disks
ES2185117T3 (en) 1997-08-22 2003-04-16 Seikagaku Kogyo Co Ltd THERAPEUTIC AGENT FOR INTERVERTEBRAL DISK HERNIADO.
US6077987A (en) 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
US5948432A (en) 1997-11-26 1999-09-07 Keraplast Technologies Ltd. Keratin-based sheet material for biomedical applications and method of production
US6110487A (en) 1997-11-26 2000-08-29 Keraplast Technologies Ltd. Method of making porous keratin scaffolds and products of same
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production
US6274163B1 (en) 1998-04-08 2001-08-14 Keraplast Technologies, Ltd. Keratinous protein material for wound healing applications and method
US6224630B1 (en) * 1998-05-29 2001-05-01 Advanced Bio Surfaces, Inc. Implantable tissue repair device
US6746485B1 (en) * 1999-02-18 2004-06-08 St. Francis Medical Technologies, Inc. Hair used as a biologic disk, replacement, and/or structure and method
US6113639A (en) 1999-03-23 2000-09-05 Raymedica, Inc. Trial implant and trial implant kit for evaluating an intradiscal space
US6110210A (en) 1999-04-08 2000-08-29 Raymedica, Inc. Prosthetic spinal disc nucleus having selectively coupled bodies
JP2001087754A (en) 1999-09-24 2001-04-03 Relief Fund For Oil Pollution Damage In Fishing Ground Powdery composition for biological restoration of contaminated soil
MXPA04000453A (en) 2001-07-17 2004-10-27 Keratec Ltd The production of soluble keratin derivatives.
US7465321B2 (en) 2001-08-31 2008-12-16 Keratec Limited Production of biopolymer film, fibre, foam and adhesive materials from soluble S-sulfonated keratin derivatives

Also Published As

Publication number Publication date
NZ528749A (en) 2006-06-30
US20020029083A1 (en) 2002-03-07
EP1383444A4 (en) 2008-02-13
JP2004526501A (en) 2004-09-02
US6783546B2 (en) 2004-08-31
WO2002076336A3 (en) 2003-02-27
WO2002076336A2 (en) 2002-10-03
EP1383444A2 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
US6783546B2 (en) Implantable prosthetic or tissue expanding device
US6371984B1 (en) Implantable prosthetic or tissue expanding device
JP2530089B2 (en) Hydrogel disc nucleus
Domanskis et al. Histological investigation of the etiology of capsule contracture following augmentation mammaplasty
AU674497B2 (en) Prosthesis with improved biocompatibility
US20220313871A1 (en) Shapeable scaffold material and uses thereof
US7332117B2 (en) Ion treated hydrogel
AU2002306780A1 (en) Implantable prosthetic or tissue expanding device

Legal Events

Date Code Title Description
FZDE Discontinued